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ABSTRACT 
 
The cardiac sodium channel α subunit Nav1.5 (encoded by the SCN5A gene) 
plays an important role in the generation and propagation of electrical signals in the heart, 
and can cause cardiac arrhythmias, heart failure and sudden death when mutated or 
dysregulated.  However, the precise composition of the multi-protein complex for the 
sodium channel has not been completely defined.  The molecular mechanisms by which 
Nav1.5 mutations cause cardiac arrhythmias have not yet been well-studied in vivo.  It 
remains to be explored whether Nav1.5 is expressed in other tissues and plays novel roles 
in other tissues or organs.  This dissertation addresses these aspects of Nav1.5 regulation.   
I found that MOG1, a small protein that is highly conserved from yeast to humans, 
is a central component of the channel complex and distinctly modulates the physiological 
function of Nav1.5. A yeast two-hybrid screen identified MOG1 as a new protein that 
interacts with the cytoplasmic loop II (between transmembrane domain DII and III) of 
Nav1.5.  The interaction was further demonstrated by both in vitro GST pull-down and in 
vivo co-immunoprecipitation assays.  Co-expression of MOG1 with Nav1.5 in HEK293 
cells increased sodium current densities, whereas two siRNAs that knocked down 
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expression of MOG1 decreased current densities.  In neonatal myocytes, over-expression 
of MOG1 increased current densities nearly two-fold, and MOG1 siRNAs down-
regulated the sodium currents.  Immunostaining revealed that in the heart, MOG1 was 
expressed in both atrial and ventricular tissues and was highly localized in the 
intercalated discs.  These results suggest that MOG1 may be a critical regulator of 
sodium channel function in the heart and reveal a new function for MOG1.  Furthermore, 
I showed that MOG1 increased sodium current density by increasing cell membrane 
localization of Nav1.5.  This study further demonstrates the functional diversity of 
Nav1.5-binding proteins, which may be important for the function of Nav1.5 under 
different cellular conditions. 
The second major project I worked on was identification by microarray analysis 
of genes differentially expressed in transgenic mice with cardiac expression of LQTS 
mutation N1325S of SCN5A.  I identified 33 genes in five different functional groups 
that showed differential expression.  STAT1, which encodes a transcription factor 
involved in apoptosis and interferon response, showed the most significant difference of 
expression between TG-NS and control mice (a nearly 10-fold increase in expression, P = 
4 x 10-6).  The results were further confirmed by quantitative real-time PCR and Western 
blot analyses.  Accordingly, many interferon response genes also showed differential 
expression in TG-NS hearts.  This study represents the first microarray analysis for LQTS 
and implicates STAT1 in the pathogenesis and progression of LQTS and heart failure 
developed in the transgenic mice.   
The third project focused on the distribution of Nav1.5 protein in the mouse brain 
which was investigated using immunohistochemistry.  Immuno-staining with a Nav1.5-
 vii
specific antibody revealed that Nav1.5 protein was localized in certain distinct regions of 
brain including the cerebral cortex, thalamus, hypothalamus, basal ganglia, cerebellum 
and brainstem.  Notably, I found that Nav1.5 protein co-localized with neurofilaments 
and clustered at a high density in the neuronal processes, mainly axons.  These results 
suggest that Nav1.5 protein may play a role in the physiology of the central nervous 
system (generation and propagation of electrical signals by axons).    
These studies on Nav1.5 provide new insights into the regulation of the function 
of Nav1.5, and shed light on the possible pathogenetic mechanism of cardiac arrhythmias 
at the molecular level.    
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CHAPTER I 
 
 
GENERAL INTRODUCTION 
 
1.1. Sodium channel Nav1.5 and its functions 
1.1.1. Sodium channel gene family   
Voltage-gated sodium channels are transmembrane proteins that are critical to the 
generation and rapid propagation of the electrical signals (action potentials) in excitable 
membranes of cardiomyocytes, neurons, and other cells.  To date at least twelve different 
sodium channel α-subunit genes have been cloned and they include SCN1A (brain, 
chromosome 2q23-q24), SCN2A (brain, 2q22-q23), SCN3A (brain and dorsal root 
ganglion or DRG, 2q24-q31), SCN4A (skeletal muscle, 17q23.1-q25.3), SCN5A (heart, 
3p21), SCN6A (uterus and heart, 2q21-q23), SCN7A (glial cells, DRG, 2q21-23), SCN8A 
(brain, DRG and spinal cord, 12q13), SCN9A (DRG, brain and spinal cord, 2q24), 
SCN10A (DRG, 3p22-24), SCN11A (DRG, 3p21-24), and SCN12A (central nervous 
system, DRG, non-neural tissues, 3p23-p21.3) (George et al. 1992; Jeong et al. 2000; 
Novakovic et al. 2001; Ogata et al. 2000; Wang et al. 1996).  The sodium channels are 
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related to the founder member, the voltage-gated sodium channel from the electric eel 
electroplax, and also related to each other by sequence homology and a conserved 
structure consisting of four transmembrane domains, each of which is composed of six 
transmembrane segments (Balser et al. 1999; Catterall  et al. 2000; Wang et al. 1996; 
Wang et al. 1995a).  Dysfunction of sodium channels causes multiple human diseases.  
Mutations in the cardiac sodium channel gene SCN5A cause cardiac arrhythmias and 
sudden death associated with long QT syndrome (LQTS), idiopathic ventricular 
fibrillation and Brugada syndrome, and cardiac conduction disease (Chen et al. 1998; 
Dumaine  et al. 1996; Schott  et al. 1999; Tan  et al. 2001; Wan  et al 2001; Wang  et al. 
2000; Wang  et al . 2001; Wang  et al. 1995a).  Mutations in the skeletal muscle sodium 
channel gene SCN4A cause hyperkalemic periodic paralysis and paramyotonia congenital 
(Ptacek  et al. 1992; Ptacek  et al. 1991).  Mutations in the brain sodium channel gene 
SCN1A, SCN2A and SCN3A cause generalized epilepsy with febrile seizures type 2 
(Escayg et al. 2000).   
Based on the channel sensitivity to blockade by TTX on the connecting segment 
between S5 and S6, the tetrodotoxin (TTX) binding site, sodium channels are classified 
into three types:  TTX-sensitive sodium channels (TTXs; TTX, IC50=1-5 nM), TTX-
resistant Na channels (TTXr; 0.2-1 µM TTX), and TTX-insensitive Na channels (TTXi; 
30-100 µM TTX) (Donahue et al. 2000, Fozzard et al. 1996).  The Nav1.5 channel 
encoded by SCN5A gene is TTX-resistant (Gellens et al. 1992).  TTXr Na channels 
generate currents that are slower, but recover from inactivation much faster than those 
from TTXs channels (Elliott et al. 1993), suggesting a possible role of TTXr sodium 
channels in sustained firing of neurons or as pace-makers. 
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1.1.2. Cardiac sodium channel Nav1.5 
The human cardiac sodium channel Nav1.5 belongs to the voltage-gated sodium 
channel family, and is encoded by the SCN5A gene.  This gene is located on chromosome 
3p21 and contains 27 introns and 28 exons (Gellens et al. 1992).  The human SCN5A 
gene has two alternatively spliced variants, Nav1.5c and Nav1.5d.  Nav1.5c contains 2,015 
amino acids without glutamine at position 1077 compared to wild type Nav1.5 with 2,016 
amino acids, while Nav1.5d has a 40 amino acid deletion in the intracellular loop II 
between domain II and domain III (Gellens et al. 1992, Makielski JC et al. 2003, 
Camacho et al. 2006).  The cardiac sodium channel Nav1.5 was initially cloned from the 
human cardiac cDNA library.  Nav1.5 is mainly expressed in the heart, although it is also 
expressed in brain, DRG and skeletal muscle at a much lower level (Gellens et al. 1992, 
Hartmann et al. 1999, Plummer et al. 1999).  Nav1.5 is highly homologous to Nav1.8 
(82%) and Nav1.9 (72%), which are mainly expressed in the peripheral nervous system 
(Plummer et al. 1999, Kerr et al. 2004) on the amino acid level.  
Nav1.5 is the pore-forming α subunit of the cardiac sodium channel.  It consists of 
four homologous domains (I-IV) with each domain composed of six transmembrane α-
helices (Fig. 1.1).  There are at least four different β-subunits, β1, β2 β3 and β4, that are 
associated with the α subunit.  The β1 subunit has been detected in skeletal muscle, heart 
and brain tissues (Makita et al. 1994), whereas the β3 subunit has been identified in the 
brain, kidney, skeletal muscle and heart (Morgan et al. 2000, Stevens et al. 2001).  The β2 
and β4 subunits are also expressed in the heart, but at significantly lower levels than those 
in the brain (Maier et al. 2004; Eubanks et al. 1997, Malhotra et al., 2001, Yu et al., 2003).  
The structure of β1 is most similar to that of the β3 subunit with a noncovalent link to the 
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α subunit (Isom et al., 1992, Morgan et al., 2000, Qu et al., 2001).  The β2 and β4 
subunits are more similar to each other with an unpaired cysteine that interacts with the α 
subunit by a disulfide bond (Hartshorne et al., 1984, Yu et al., 2003).  The β1 and β2 
subunits are similar to cell adhesion molecules in their extracellular immunoglobulin-like 
motifs (Isom et al.1996), which is consistent with their function for regulating the 
targeting and localization of the sodium channel to the cell membrane (Novakovic et al. 
2001).   
 
1.1.3. Functional characterization of cardiac sodium channel Nav1.5 
The major functions of Nav1.5 are to generate the cardiac action potential and to 
maintain rapid conduction of electrical signals through cardiac tissues.  This voltage–
gated sodium channel exists in three main transitional states: closed, open (activated) and 
inactivated.  These channel states control sodium ion permeability through the channel 
into the cardiac cell.  Sodium channel acticvation allows sodium ion influx into the cell 
and inactivation blocks entry of inward sodium ions.  Inactivation is mediated by the 
inactivation gate, a cytoplasmic link between domain III and domain IV where the triad 
IFM (Ile 1488, Phe 1489, Met 1490) serves as a hydrophobic ‘latch’ that limits or 
restricts sodium ion pass through the pore (West et al. 1992).  When the cell membrane 
senses a voltage change (i.e., depolarization), the voltage sensor (the S4 segment) moves 
outward (towards external face).  Following this change, the four transmembrane 
domains (I-IV) undergo several conformational changes whereby the overall channel 
conformation is in the open state. The sodium ions enter the cells rapidly, which initiates 
the cardiac action potential.  Several milliseconds later, the inactivation 
 4
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1.  The structure of Nav1.5.  Sodium channel Nav1.5 consists of four 
transmembrane domains (I-IV) and five cytoplasmic domains.  Each transmembrane 
domain contains six alpha-helix segments (S1-S6). Cytoplasmic domains are composed 
of the N-terminus, loops I, II, III and C-terminus. 
 
 
 
 
 
 
 5
gate closes and blocks movement of sodium ions across the cell membrane.  The sodium 
channel is then converted to the inactivated state.  The recovery of the sodium channel to 
reopen is voltage-dependent.  Highly polarized (-80 to 90 mV) cell membrane can be 
depolarized rapidly by stimuli due to more sodium channels reopening.  While partially 
depolarized cells with potentials close to threshold -70 mV causes a much slower 
upstroke because of the inactivation of some channels.  The recovery of channels from 
inactivation is also time-dependent.  Sodium channels typically activate within 200-300 
µs and inactivate completely within 2-5 ms.   
     
1.1.3. 1.  Nav1.5 and the cardiac action potential 
     The cardiac action potential refers to changes in voltage that travel along the 
membrane of the cardiac cell.  These changes are composed of 5 phases (0-4) which 
collectively make up the cardiac action potential.  The sodium channel makes a 
contribution in two phases of the action potential, the upstroke of rapid depolarization or 
phase 0 and the plateau phase or phase 2 (Fig. 1.2).  Phase 3 is the repolarization phase.  
Phase 4 is the resting phase with a membrane potential of approx -90 mV in ventricular 
myocardium, which is sustained until the cell is stimulated by an external stimulus.  
During phase 4, most sodium channels are in the closed state, the activation gate is in the 
closed state and the inactivation gate is in an open state.  Upon the external stimulus, the 
membrane potential of the cell achieves a threshold voltage (about -70 mV) and initiates 
the rapid depolarization phase (Phase 0) by the activation of the sodium channels.  When 
the cell is depolarized, the channel is changed from a closed state to the open state.  In 
this open conformation, both the activation and inactivation gates are shifted to their open  
 6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2.   A schematic view of an idealized action potential for ventricular myocytes.   
The action potential has 5 phases (numbered 0-4). Phase 4 is the resting membrane 
potential, in which the cell is not stimulated, mainly maintained by the movement of K+.  
Phase 0 is the rapid depolarization phase due to the rapid influx of Na+.  Phase 1 occurs 
with the inactivation of the fast Na  channels+  and efflux of K+.  Phase 2 is the "plateau" 
phase sustained by a balance between inward movement of Ca2+ and outward movement 
of K+.  Phase 3 is the repolarization phase due to the outward IK caused by the opening of 
the slow delayed rectifier (IKs) K  channels+ , and the rapid delayed rectifier K+ channels 
(IKr). 
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state.  Sodium ions permeate across the channel pore.  This is quickly followed by 
inactivation of the channels (Phase 1) and the opening of the transient outward K+ 
channel.  Delayed sodium channel inactivation can cause late sodium currents and 
prolong action potential duration (APD).  Phase 2 of the action potential represents the 
"plateau" phase maintained by the influx of Ca2+ ions through L-type calcium channels, 
the influx of sodium ions through sodium channel and Na/Ca exchanger and the efflux of 
K+ ions through the slow delayed rectifier potassium channels, IKs.  During Phase 3, the 
slow delayed rectifier (IKs) and rapid delayed rectifier (IKr) K  channels+  remain open and 
the L-type Ca  channels2+  are inactivated.  After membrane repolarization, the sodium 
channels convert back to their resting or closed state. 
The cardiac electrical impulse originates from the sinoatrial node pacemaker cells 
that depolarize spontaneously.  The impulse is conducted to and through the atria to the 
atrioventricular junction, and then propagates to ventricles via the right/left bundle 
branches and Purkinje fibers.  Voltage-gated sodium channels, mainly Nav1.5, play a key 
role for impulse propagation and conduction.    
Sodium ionic currents can be measured under voltage clamp at the whole cell 
membrane level, referred to as whole cell patch clamp, a broadly used method to measure 
membrane currents from isolated cells.  A typical laboratory setup is shown in Fig. 1.3. 
 
1.1.3.2. Nav1.5 and the excitation-contraction coupling (ECC) process 
After the cell depolarizes, L-type voltage-dependent calcium channels on the cell surface 
open and allow calcium ions to enter the cell.  This small amount of calcium entry 
stimulates calcium-release channels named ryanodine receptors (RYR2) and triggers a 
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cell
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_
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Fig. 1.3 Schematic diagram for a typical electrophysiological laboratory set-up. 
The set-up represents a technique for studying ionic currents at the cellular level. A glass 
pipette is pressed gently on the cell membrane to form a seal. When suction is applied to 
the pipette the membrane breaks and the cytoplasm and pipette solution start to 
equilibrate. Cells are voltage-clamped and currents are recorded with the help of 
hardware (computer and amplifier) and software (pClamp9.0).   
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subsequent release of a larger amount of calcium ions stored in the sarcoplasmic 
reticulum (SR).  The free calcium ions bind to troponin-C (TN-C), one of the triple 
regulatory complexes attached to the thin filaments, inducing a conformational change 
and relieving inhibition on the actin-myosin crossbridge by troponin I.  These changes 
result in a movement between the myosin heads and the actin and cause muscle 
contraction.  This physiological process that converts an electrical stimulus to a 
mechanical response has been named excitation-contraction coupling (Sandow, 1952).  
Recent work has shown that late sodium currents generated by the mutant sodium 
channel N1325S of Nav1.5 may lead to intracellular calcium overload (Yong et al. 2007).  
Irregularities in Ca2+ transients caused by the altered sodium currents may affect cardiac 
cell contractility. 
 
1.2. Cardiac diseases associated with the SCN5A gene 
Mutations in the cardiac sodium channel gene SCN5A have been linked to the 
pathogenesis of several serious cardiac diseases.  Appendix A summarizes the Nav1.5 
mutations associated with cardiac diseases. The relationship between Nav1.5 mutations 
and the physiological functions associated with the corresponding cardiac diseases is 
described as follows. 
 
1.2.1.  The Long QT Syndrome (LQTS)   
      The long QT syndrome (LQTS) is characterized by prolongation of the QT 
interval and T wave abnormalities on electrocardiograms (ECG) and it is associated 
symptoms including syncope and sudden death caused by a specific ventricular 
 10
arrhythmia, torsade de pointes (Schwartz et al. 1975; Wang et al. 1997).  Two major 
clinical forms of LQTS have been described based on genetic transmission patterns: 
autosomal dominant LQTS (Romano-Ward syndrome) with normal hearing (Ward et al. 
1964; Romano et al. 1965) and the much rarer autosomal recessive LQTS (Jervell-Lange-
Nielsen syndrome) that is associated with congenital neural deafness (Jervell et al. 1957).  
LQTS can also be sporadic and acquired (Towbin et al. 2001).  Although most clinical 
symptoms are “triggered” by strong emotional outpouring, exercise and sudden 
awakening from sleep, syncope and sudden death can also occur during sleep or at rest 
(Keating et al. 2001).   
 
1.2.1.1. Genetics of long QT syndrome (LQTS) 
    During the past decade, nine LQT genes have been discovered.  KCNQ1 (LQT1, 
mapped to chromosome 11p15.5) (Wang et al. 1996, Keating et al. 1991), KCNH2 (LQT2, 
on chromosome 7q35-36) (Curran et al. 1995, Jiang, 1994), KCNE1 or MinK (LQT5, on 
chromosome 21q22) (Splawski et al. 1997, Schulze-Bahr et al. 1997), KCNE2 or MiRP1 
(LQT6, on chromosome 21q22 ) (Abbott et al. 1999), KCNJ2 (LQT7, on chromosome 
17q23) (Tristani-Firouzi et al. 2002, Plaster er al. 2001) all encode potassium channel 
subunits.  SCN5A (LQT3, on chromosome 3p21-24) gene has been shown as the 
chromosome 3-linked LQT gene (3p24-p21), and encodes the cardiac sodium channel 
protein (Wang et al. 1995a, Jiang, 1994).  The LQT8 gene is CACNA1C mapped to 
chromosome 12p13, which encodes the alpha 1c subunit of voltage-gated cardiac L Type 
calcium channel (Splawski et al. 2004, Jacobs et al. 2006).  The first non ion channel 
gene to be linked to the LQTS (LQT4, on chromosome 4q25-27) is ANK2, a gene 
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encoding ankyrin-B, a member of a family of versatile membrane adapters (Mohler et al. 
2003, Schott et al. 1995).  Recent research work reported CAV3, a gene encoding 
caveolin-3, an ion channel-associated protein, as a novel LQTS gene (LQT9, on 
chromosome 3p25) (Vatta et al. 2006).  Heterozygous mutations in all these genes cause 
autosomal dominant LQTS (Romano-Ward syndrome).  Among LQTS patients, 40-45% 
have KCNQ1 mutations, 40-45% have KCNH2 mutations, and 5-8% have mutations in 
SCN5A.  Less than 1% of clinical cases are reported to have rare LQTS forms, which 
include LQT4, LQT5, LQT6, LQT7, LQT8, and LQT9 (Zareba W 2006, Vatta et al. 
2006).  Homozygous mutations in KvLQT1 and KCNE1 result in autosomal recessive 
LQT (Jervell-Lange-Nielsen syndrome) (Splawski et al. 1997; Neyroud et al. 1997).  
 
1.2.1.2. SCN5A mutations and LQT3     
     Long QT syndrome type 3 (LQT3) results from gain-of-function mutations in the 
cardiac sodium channel Nav1.5.  A late persistent inward current is a common 
electrophysiological property of mutations in Nav1.5 leading to LQTS.  This late sodium 
current results in a gain of sodium current during the plateau of the action potential, and 
thus results in a longer plateau phase of the cardiac action potential and a prolongation of 
the Q-T interval. (Bennett et al. 1995, Clancy et al. 1999).  To date, there are at least 
forty-seven mutations reported to be associated with LQT3 (Appedix A).  These 
mutations include thirty-eight missense mutations, six deletion mutations, one splice 
mutation and two insertion mutations.  Among them, 15 mutations are located in Domain 
IV.  The most studied of these mutations are Nav1.5-∆KPQ, Nav1.5-N1325S, Nav1.5-
R1644H, Nav1.5-D1790G and Nav1.5-I1768V.  Nav1.5-∆KPQ, Nav1.5-N1325S and 
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Nav1.5-R1644H mutations cause persistent late inward sodium currents and exhibit 
prolonged APD, which are due to dispersed reopenings or long-lasting bursts (Dumaine 
et al. 1996).  In contrast, both Nav1.5-D1790G and Nav1.5-I1768V do not enhance 
sustained inward currents (An et al. 1998, Rivolta et al. 2002).  Mutant channels with 
Nav1.5-D1790G cause the prolonged APD by increasing [Ca ]  transient2+ i  at slow heart 
rates (Wehrens et al. 2000), and Nav1.5-I1768V induces prolonged APD by enhancing 
recovery from inactivation and changing the steady-state inactivation kinetics (Rivolta et 
al. 2002).  
 
1.2.1.3. Mouse models for LQT3     
      Several SCN5A mutations have been characterized in either transgenic 
overexpression or knock-in mice.  Three mouse models for LQT3 have been established: 
SCN5A-∆KPQ knock-in, SCN5A-1795insD knock-in and SCN5A-N1325S transgenic 
overexpression models (Nuyens et al. 2001, Remme et al. 2006, Tian et al. 2004).      
Wang et al. identified the ∆KPQ mutation first in two unrelated LQT3 families 
(Wang et al. 1995), and later found the same mutation in two other unrelated families 
(Wang et al. 1995b).  The ∆KPQ mutation is the first SCN5A mutation identified in 
humans and is located in the highly conserved portion of the cytoplasmic III-IV linker, 
the putative channel inactivation gate.  The stability of inactivation of the cardiac sodium 
channel during prolonged depolarization was reported to be decreased in mutant channels 
with the ∆KPQ mutation, which resulted in prolongation of APD and facilitated the 
development of arrhythmogenic early afterdepolarizations (EADs) (Bennett et al. 1995).  
This SCN5A-delKPQ mutation was further overexpressed in mice (Nuyens et al. 2001).  
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Homozygous embryos (SCN5A∆/∆) died at embryonic day 10.5 when SCN5A becomes 
important for cardiac excitability.  Mice heterozygous for knock-in ∆KPQ (SCN5A∆/+) 
exhibited the typical LQT3 features including prolonged action potential and QT 
intervals, low resting heart rate, early afterdepolarization, ventricular arrhythmias and 
sudden death (Nuyens et al. 2001).  Increased late inward sodium currents during the 
plateau phase of action potential were blocked by mexiletine, a sodium channel blocker.  
Ventricular tachyarrhythmias and ventricular extrasystoles were the results of prolonged 
action potential duration and EAD in SCN5A∆/+ mice (Nuyens et al. 2001).   
The second mouse model for a LQTS mutation is the SCN5A 1795insD/+ mouse.  
This mutation results from an insertion of an aspartic acid in the C-terminus of SCN5A.  
This mutation was identified in a Dutch family with a high incidence of LQT3 and 
Brugada syndrome (Bezzina et al.1999).  Expression of 1795insD mutation in Xenopus 
oocytes and HEK293 cells reduced sodium current amplitude, changed channel kinetics 
characterized by a positive shift of the activation curve, a negative shift of the 
inactivation curve, disruption of fast inactivation and delayed recovery of sodium channel 
from inactivation (Bezzina et al.1999, Marieke et al. 2000).  This mutation also enhances 
channel bursting, leading to a persistent component of noninactivating current (Clancy et 
al. 2002).  Heterozygous mice expressing 1795insD, SCN5A1795insD/+, exhibited 
bradycardia, increased PQ interval, prolonged QRS duration and QT interval compared 
with wild-type mice on ECG (Remme et al. 2006).  Epicardial mapping in Langendorff-
perfused hearts displayed conduction delay in the right ventricle of SCN5A1795insD/+ mice 
(Remme et al. 2006).  Whole cell patch clamp revealed reduction in peak sodium current 
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density,  prolongation of the action potential and a delayed time course of current decay 
in SCN5A1795insD/+ cardiomyocytes (Remme et al. 2006).   
The Nav1.5 N1325S mutation is another well-studied LQT mutation, which 
involves a substitution of an asparagine residue by a serine at position 1325 in the 
intracellular region between domains DIII S4 and DIII S5.  Expression of this mutation in 
Xenopus oocytes and HEK293 cells produced persistent late currents and prolonged APD 
which can be inhibited by mexiletine and tetrodotoxin (Dumaine et al.1996; Wang et 
al.1997). Tian et al. in our laboratory developed a LQT3 mouse model by transgenic 
overexpression of Nav1.5 N1325S mutation in the mouse heart using a murine, cardiac 
specific α-myosin heavy chain promoter.  The LQT3 phenotypes including prolonged QT 
interval, syncope, ventricular tachycardia, ventricular fibrillation, and sudden death were 
observed in the transgenic mice.  Prolonged APD due to the late persistent sodium 
current, EAD and a slow recovery from inactivation of INa were detected in transgenic 
ventricular myocytes (Tian et al. 2004).    
 
1.2.2. Brugada syndrome   
Brugada syndrome is one of the commonly recognized forms of idiopathic 
ventricular fibrillation (IVF).  IVF refers to ventricular fibrillation occurring without 
underlying structural heart disease, metabolic abnormalities or QT interval prolongation 
on ECG (Jalife 2000; Viskin et al. 1990).  Two commonly recognized forms of IVF 
include: (1) IVF with normal ECG; (2) Brugada syndrome with characteristic ECG 
features of right bundle branch block (RBBB) and persistent ST segment elevation (STE) 
in leads V1 to V3 (Viskin et al 1998). 
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    Brugada syndrome has been estimated to be responsible for 18-30% of all sudden 
deaths and at least 20% of patient death with a normal heart structure (Antzelevitch et al. 
2005).  Brugada syndrome can be caused by SCN5A mutations (Chen et al 1998).  
SCN5A mutations associated with Brugada syndrome act by a loss-of-function 
mechanism.   
    The SCN5A mutations in patients with Brugada syndrome result in different 
electrophysiological abnormalities compared with those known to cause LQTS or 
conduction system disease.  Mutations in the coding region of SCN5A in three IVF 
families were identified in 1998 and those patients have typical ST segment elevation and 
RBBB ECG pattern (Chen et al.1998).  Later a novel SCN5A mutation (S1710L) was 
identified in IVF patients without STE and RBBB on ECG (Akai et al.2000).  Research 
revealed more than one hundred SCN5A mutations linked to Brugada syndrome and these 
mutations are located throughout the SCN5A gene (Appendix A).  Most of them are 
exonic mutations including seventy-two missense mutations, four deletions, four 
frameshifts and one insertion.  There are seven mutations in introns affecting RNA 
splicing.  The physiological effects of SCN5A mutations for Brugada syndrome are more 
complicated than those for LQTS because heterologously expressed sodium channel 
mutants displayed a broad variety of functional properties (Akai et al. 2000).  For 
example, shifts in the voltage-dependence of activation and inactivation are not always 
consistent with loss of function.  R1512W and S1710L shift the steady-state inactivation 
curve to more hyperpolarizing potentials (Rook et al. 1999, Akai et al. 2000), and 
A1924T causes a hyperpolarizing shift of the activation curve (Rook et al. 1999).  In 
contrast, the first mutation T1620M gave a depolarizing shift of steady-state inactivation 
 16
curve when expressed in Xenopus oocytes (Chen et al.1998, Baroudi et al. 2000), but no 
effects on inactivation curve when expressed in mammalian  tsA201 cells (Baroudi et al. 
2000).  Most missense and splice-donor mutations lead to a faster recovery from 
inactivation (Chen et al. 1998, Herbert et al. 2006), while frameshift mutations inactivate 
the channel, causing a non-functional channel (Chen et al.1998).   
 
1.2.3.  Progressive cardiac conduction defect 
  Loss-of-function mutations in SCN5A were also identified in patients with 
progressive cardiac conduction defects (PCCD), also known as Lev-Lenegre disease 
(Probst et al. 1999).  The progressive cardiac conduction defect is one of the most 
common cardiac conduction disturbances characterized by progressive alteration of 
cardiac conduction through the His-Purkinje system with prolonged QRS complexes 
(Probst et al. 1999).  Patients may suffer from syncope or sudden death due to complete 
atria-ventricular block.  This disease affects the conductive tissue associated with 
myocardial rearrangement and fibrosis (Royer et al. 2005).  Affected conduction 
parameters are P wave, PR and QRS interval duration which increases with age (Probst et 
al. 2003 and 2006, Royer et al. 2005).  Ten mutations in SCN5A have been identified in 
patients with the cardiac conduction defect (Appendix A).  These mutations include 
seven exonic mutations, one frameshift and two splicing mutations.  The first SCN5A 
mutation related to PCCD was found in the highly conserved +2 donor splicing site of 
SCN5A intron 22 in a French family.  The T→C substitution mutation results in abnormal 
transcriptional products with the deletion of exon 22, which encodes the voltage-sensitive 
S4 segment in domain III and results in a non-functional channel (Schott et al.1999, 
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Probst et al. 2003).  Surprisingly, three missense and one splicing SCN5A mutations were 
reported to cause Brugada syndrome and isolated cardiac conduction defect as well 
(Kyndt et al. 2001, Smits et al. 2005, Rossenbacker 2004 and 2005).  Recently, it was 
found that the severity of symptoms increase with age in PCCD patients with SCN5A 
mutation W1421X (LQT3).  An SCN5A polymorphism R1193Q was reported to 
complement the clinical manifestations of the cardiac conduction defect caused by 
nonsense SCN5A mutation W1421X (Niu et al. 2006).  Therefore, the mechanism for 
PCCD seems complex. 
 
1.2.4. Sudden infant death syndrome (SIDS) 
      Sudden infant death syndrome (SIDS) is defined as sudden and unanticipated death 
of an infant younger than one year (Plant et al. 2006).  The death is unexplained after a 
thorough investigation, including a complete autopsy and a review of the clinical history.  
SIDS is one of the leading causes of infant mortality during the first year of life in 
developed countries (Tester et al. 2005).  The pathogenesis of SIDS is multifactorial, and 
involves abnormalities in respiratory, cardiac, endocrine and potential neurological 
functions (Makielski 2006).  Prolongation of the QT interval was first detected in 39% of 
the siblings and 11 (26%) of parents of infants with SIDS (Maron et al. 1976).  SIDS was 
previously considered as a form of LQT3 in infants (Moric et al. 2003).  Mutation 
screening for all known LQTS genes in SIDS identified a SCN5A mutation A1330P, 
which increased channel availability and induced faster recovery from inactivation 
(Wedekind et al. 2001).  Another mutation screen of seven LQTS genes found that 9.5% 
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of SIDS patients carried LQTS gene variants, which included four SCN5A mutations (del 
AL 586-587, R680H, T1304M, F1486L) and 5 rare genetic variants (S216L, R1193Q, 
V1951L, F2004L, P2006A) (Arnestad et al. 2007).  All of these variants showed defects 
in the voltage-dependent of inactivation (Wang et al. 2007).  Expression of S1103Y in 
HEK293 cells under different pH demonstrated that acidosis was involved in SIDS, 
which is consistent with clinical observations (Plant et al. 2006).  Prenatal findings and 
postpartum electrocardiograms strongly suggested that sinus bradycardia was related to 
severe prolongation of the QTc in infants with SIDS (Schwartz et al. 2000, Beinder et al. 
2000).  In addition, recent research work showed that mutations in caveolin-3 are also 
linked to SIDS, and cause LQT3-like phenotype with an increased late sodium current 
(Cronk, 2007). 
 
1.2.5. Sinus node dysfunction   
      Sinus node dysfunction (SND) is also called sick sinus syndrome which is 
accompanied by symptoms such as dizziness or syncope.  This syndrome is caused by a 
malfunction of the sinus node.  The sinus node cell is characterized by initiation of the 
automatic depolarization.  Calcium channels (Ica,T, Ica,L) make the major contribution for 
the action potential upstroke of nodal cells in the center of nodal tissue.  In contrast, 
sodium channels play a major role in pacemaking in the periphery of sinus node (Kodama 
et al. 1997).  Mutations in the cardiac sodium channel gene SCN5A were found to cause 
sinus node dysfunction.  Mutational screening in ten pediatric patients with sick sinus 
syndrome from seven families identified six mutations (T220I, P1298L, G1408R, 
delF1617, R1623X, and R1632H).  Electrophysiological studies by expression of these 
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mutations (T220I, P1298L, delF1617 and R1632H) in tsA201 cells identified a loss of 
channel function, including a reduced peak sodium current density, hyperpolarizing shifts 
in the voltage dependence of steady-state channel availability, and slow recovery from 
inactivation (Benson et al. 2003).  The nonsense mutation (R1623X) produced 
nonfunctional channels and missense mutation G1408R was demonstrated to silence the 
sodium channel function (Benson et al. 2003; Kyndt et al. 2001).  These results suggest 
that SCN5A mutations reduce myocardial excitability in patients with sinus node 
dysfunction. 
 
1.2.6. Atrial dysfunction 
      Mutations in SCN5A have been linked to atrial dysfunction, including atrial 
standstill and atrial fibrillation.  Atrial standstill is a rare arrhythmogenic condition 
characterized by the absence of electrical and mechanical activity in the atria.  Genetic 
analysis for a patient with Brugada syndrome accompanied by atrial standstill revealed a 
missense mutation (R367H) in SCN5A.  The mutant sodium channel was nonfunctional 
when expressed heterologously in Xenopus oocytes (Takehara et al. 2004).  SCN5A 
mutation L212P is another mutation associated with a severe clinical phenotype in atrial 
standstill (Makita et al. 2005).  The heterologously expressed L212P mutant channel in 
tsA-201 cells exhibited a hyperpolarization shift of steady-state inactivation and delayed 
recovery from inactivation.  Coinherited atrial-specific gap junction connexin 40 (Cx40) 
SNPs with SCN5A mutation L212P may enhance the severity of symptoms by disrupting 
the spatial distribution of Cx40 and thus influence atrial conduction and excitability 
(Makita et al. 2005).  Therefore, SCN5A mutations contribute to the development of atrial 
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standstill by reducing sodium channel availability and slowing cardiac impulse 
conduction.   
    Atrial fibrillation (AF) is another atrial dysfunction associated with SCN5A 
mutations.   A common loss-of-function H558R polymorphism in SCN5A, which is 
presented in one-third of the population, was reported to be more common in AF patients 
than in controls (Chen et al. 2007).  In a dog model of chronic atrial fibrillation, the 
sodium current density decreased with slowing of recovery kinetics in atrial cells (Yagi et 
al. 2002).  SCN5A mutations were also identified in patients with both dilated 
cardiomyopathy and atrial fibrillation (Olson et al. 2005).   
 
1.2.7. Heart failure    
     Heart failure is a condition in which the heart is unable to pump a sufficient 
amount of blood to meet the needs of the body, which may result from any abnormality 
of cardiac structure or function.  In a dog model of heart failure induced by sequential 
coronary microembolization, the expression of Nav1.5 protein was reduced about 30% 
and sodium current density was decreased significantly (Zicha et al. 2004).  Mutations in 
SCN5A have been shown to increase the risk for dilated cardiomyopathy and heart 
failure with atrial fibrillation (Olson et al. 2005). 
 
1.3. Regulation of Nav1.5 
        The mechanisms that underlie modulation of sodium channel functions have been 
complex and vary according to the sodium channels studied.  Research work over last 
several years identified a few Nav1.5 regulatory proteins (Fig. 1.4).  They include 
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auxiliary β subunits, C-terminal interacting proteins including fibroblast growth factor 
homologous factor1B (FHF1B), calmodulin, ubiquitin-protein ligase Nedd4 and 
syntrophin/dystrophin complex, cytoplasmic loop  I interacting protein 14-3-3, and 
cytoplasmic loop II interacting protein ankyrin G.  The Nav1.5 channel can also be 
modulated by phosphorylation (Fyn, protein kinase A, protein kinase C, glucocorticoid–
inducible kinases SGK1 and SGK3) and dephosphorylation (protein tyrosin phosphatase 
H1).  I will discuss these Nav1.5 interacting proteins in detail below. 
 
1.3.1. Regulation by auxiliary β subunits 
The regulation of Nav1.5 channels by β subunits has been extensively studied.  At 
least four different β-subunits, β1, β2, β3, and β4, have been identified in the heart with 
different expression levels.  Co-expression of SCN1B (encoding β1) with Nav1.5 induced 
acceleration in the recovery from inactivation in the heart (Nuss et al. 1995).  Co-
expression of SCN5A with either SCN3b (β3) or SCN1b (β1) in Xenopus oocytes 
increased Nav1.5 expression on plasma membrane by threefold (Fahmi et al., 2001), and 
induced acceleration in the recovery from inactivation in heart (Nuss et al. 1995, Baroudi 
et al. 2000).  However, SCN3b and SCN1b have different effects on the kinetics of 
Nav1.5, with β3 causing a significant depolarizing shift in steady-state inactivation, 
whereas β1 induced faster recovery from inactivation compared to β3 subunit (Fahmi et 
al. 2001).  The β2 subunit was shown to cause a hyperpolarizing shift in Nav1.5 gating 
(Johnson et al. 2006).  Recent study showed that a mutation (L179F) in the β4 subunit 
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increased the late sodium currents, the similar effect to the LQT3 mutation, ∆KPQ 
(Medeiros-Domingo et al. 2007). 
 
1.3.2.  Regulation by protein kinases/phosphatases  
      The cardiac sodium channel has been reported to be subjected to phosphorylation 
and de-phosphorylation by kinases or phosphatases.  cAMP-dependent protein kinase A 
(PKA) and G protein stimulatory α–subunit (Gsα) modulate Nav1.5 upon β-adrenergic 
stimulation.  Activation of protein kinase A increased sodium currents derived from 
cardiac sodium channels (Schreibmayer et al.1994, Frohnwieser et al.1997).  The 
underlying mechanism may be related to an increased number of sodium channels on the 
plasma membrane.  Preincubation with two cell surface protein recycling interrupters, 
chloroquine and monensin, prevented the PKA-mediated increase of sodium currents on 
cell membrane (Zhou et al. 2000).  Further studies showed that PKA mediated 
modulation of the trafficking of sodium channels by phosphorylation of residues in the 
cytoplasmic I-II interdomain loop (Ser526 and Ser529 of Nav1.5) (Murphy et al. 1996, 
Zhou et al. 2000).  In addition, the presence of putative ER ‘retention’ signals in the I-II 
interdomain loop of the human cardiac sodium channel is also necessary for PKA– 
mediated enhancement of sodium currents (Zhou et al. 2000 and 2002).  Matsuda et al. 
reported that the N-terminus of the native Gsα was able to modulate the function of the 
cardiac sodium channel directly, i.e., independent of PKA (Matsuda et al. 1992).  Lu et al. 
further found that the mechanism was an increase of the number of sodium channels   
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Fig. 1.4.  Schematic representation of Nav1.5 and its associating proteins.  Ten 
proteins that have been reported to be associated with Nav1.5 are represented 
schematically. These proteins include FHF1B, calmodulin, Nedd-4-like and syntrophin 
that interact with the C-terminus of Nav1.5, ankyrin interacting with the cytoplasmic loop 
II between transmembrane domains II and III, and the 14-3-3 protein interacting with the 
loop I of Nav1.5.  Four kinases/phosphatases, PKA and PTPH1 that interact with the 
cytoplamic loop I and C-terminus respectively.  PKC and Fyn interact with loop III.  Beta 
subunits have not been shown here. This Figure was modified from Abriel et al. Trends 
Cardiovasc Med 2005;15:35–40). 
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on cell surface (Lu et al. 1999).  In contrast, activation of α-adrenergic stimulating protein 
kinase C (PKC) resulted in the reduction of sodium currents through phosphorylation of 
serine 1503 (Serine 1505 in rat) of the cardiac sodium channel (Qu et al. 1996, Tateyama 
et al. 2003).  Phosphorylation of this serine residue by PKC was further demonstrated to 
suppress the sustained sodium channel current (Isus) caused by disease-linked mutations 
(Tateyama et al. 2003).  Another tyrosine kinase Fyn has been shown to induce a 
depolarizing shift of steady-state inactivation and to accelerate the recovery from 
inactivation of Nav1.5 channels when heterologously coexpressed in HEK293 cells with 
Nav1.5 (Ahern et al. 2005).   
      Coexpression of the protein tyrosine phosphatase H1 (PTPH1) in HEK293 cells 
shifted the steady-state inactivation curve towards more hyperpolarized potentials, the 
function that is mediated by the interaction with PDZ-domain binding motif of Nav1.5 
(Jespersen et al. 2006).  Therefore, the function of the cardiac sodium channel is 
regulated by phosphorylation and dephophorylation. 
 
1.3.3.  The 14-3-3 protein interacts with the cytoplasmic I-II linker of Nav1.5  
The 14-3-3 protein is a highly conserved cytosolic protein expressed broadly in 
various  organisms and tissues.  It plays an important role in cell signaling, cell growth, 
division, adhesion, differentiation, apoptosis, and ion-channel regulation.  The 14-3-3 
protein was recently found to interact with cytoplasmic loop I between DI and DII of 
Nav1.5 (Allouis et al. 2006).  Coexpression of 14-3-3 and Nav1.5 in COS-7 cells shifted 
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the steady-state inactivation curve toward hyperpolarizing potentials and slowed the 
recovery from inactivation.    
 
1.3.4.  A protein that interacts with the cytoplasmic II-III linker of Nav1.5: 
ankyrinG   
  Ankyrins are intracellular adaptor proteins that link diverse proteins to plasma 
membrane and endoplasmic reticulum.  Ankyrin-G and ankyrin B have been shown to 
modulate the functions of the pore-forming α-subunit of sodium channel.  Lemaillet et al. 
demonstrated that ankyrin-G interacts with Nav1.5 and this interaction involved a 9-
amino acid motif in the cytoplasmic loop II conserved through vertebrate sodium 
channels (Lemaillet et al. 2003).  Further studies revealed that a Brugada syndrome 
mutation in Nav1.5 (E1053K) is located in the binding site for ankyrinG.  This mutation 
prevented the localization of the cardiac sodium channel to membrane in cardiomyocytes 
(Mohler et al. 2004). 
 
1.3.5. Proteins that interact with the C-terminal domain of Nav1.5:  FHF1B, 
calmodulin, Nedd4-like and syntrophin/dystrophin 
The C-terminal domain of Nav1.5 contains 243 amino acid residues that are 
important for interactions with several proteins including fibroblast growth factor 
homologous factor 1B (FHF1B), calmodulin (CaM), Nedd4-like ubiquitin-protein ligase, 
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and syntrophin/dystrophin ( Liu et al. 2003, Tan et al. 2002, Abriel et al 2000, Ou et al 
2003). 
 
1.3.5.1.  Fibroblast growth factor homologous factor 1B (FHF1B) 
     Fibroblast growth factor homologous factor 1B (FHF1B) belongs to a subset of 
the fibroblast growth factor (FGF) family, one of the largest families of polypeptide 
growth factors.  Recent research showed that the C-terminus of both Nav1.5 and Nav1.9 
interacted with the N-terminus of FHF1B (Liu et al., 2001, 2003).  Coexpression of 
FHF1B with Nav1.5 shifted the inactivation curve to hyperpolarized potentials, but the 
detailed role of FHF1B in Nav1.5 function and regulation is unknown (Liu et al., 2003).    
 
1.3.5.2.  Calmodulin   
Calmodulin (CaM) is a calcium binding protein that serves as a Ca2+ sensor 
through which increased calcium levels are translated into cellular responses by 
conformational changes of calmodulin (Nelson et al., 1998).  The interaction of CaM 
with the IQ motif at the C-terminus of Nav1.5 (I1908-R1918) is controversial with four 
studies reporting positive binding (Deschenes et al., 2002, Kim et al., 2004,  Tan et al, 
2002,  Young et al. 2005) and one report of negative binding (Herzog et al. 2003).  Data 
presented by Tan et al suggested that CaM increased slow inactivation of Nav1.5 
significantly by performing studies in tsA201 cells (Tan et al 2002).  However, 
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Deschenes et al. did not detect effects of CaM on Nav1.5 by co-expression of CaM and 
Nav1.5 in HEK293 cells (Deschenes et al. 2002).  Recent studies showed that CaM 
induced a hyperpolarizing shift in the voltage dependence of activation with CaM and 
Nav1.5 overexpressed in CHO cells (Young et al. 2005).  The explanation for these 
discrepancies might be due to the endogenous expression of different β-subunits among 
studied cells.  On the other hand, Wingo et al. proposed a different Ca2+ model for 
functional modulation of Nav1.5 by which Ca2+ regulates the function of Nav1.5 by direct 
binding to the EF-hand motif in the C-terminal domain of Nav1.5 independent of CaM.  
Another study reported that the binding of CaM to the Nav1.5 C-terminal domain 
modulated the interaction between the C-terminal domain and the inactivation gate (III-
IV linker) of Nav1.5 (Kim et al., 2004), and presented data against the direct binding 
between Ca2+ and the C-terminal domain of Nav1.5.  The mechanism for the regulation of 
Nav1.5 by Ca2+-dependent CaM thus remains to be further explored.   
 
1.3.5.3. Nedd4 and SGKs 
The ubiquitin-protein ligase Nedd4-2 was shown to interact directly with the PY 
motif (xPPxY) of Nav1.5 (van Bemmelen et al., 2004), and may be involved in regulation 
of membrane turnover of Nav1.5 by ubiquitination.  Co-expression of the ubiquitin-
protein ligase Nedd4 in Xenopus oocytes decreased the peak sodium current in wild type 
Nav1.5, but not the channel with mutated PY, suggesting that Nedd4 down-regulated 
cardiac channel abundance by direct interaction with the PY domain at the C-terminus 
(Abriel et al. 2000).  In a detailed study, human Nedd4-2 (homolog to Xenopus oocytes 
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Nedd4) decreased the expression of Nav1.5 on cell membrane by ubiquitination (van 
Bemmelen et al., 2004).  Further studies revealed that the effects of Nedd4 on Nav1.5 
could be related to the serum and glucocorticoid–inducible kinases SGK1 and SGK3.  
Coexpression of wild type SGK1 and constitutively active S422DSGK1 in Xenopus oocytes 
reversed the suppression of the endogeneous Nedd4 by phosphorylation, and thus 
modulated channel abundance in the plasma membrane and enhanced the peak sodium 
current.  In contrast, coexpression of SGK3 may have influence on the gating properties 
of Nav1.5 directly, not by inactivation of Nedd4 (Boehmer et al. 2003).  In addition, 
phosphorylation of Nedd4-2 induced the degradation of SGK (Zhou et al., 2005).  The 
degradation and internalization of Nav1.5 on cell membrane deserved further studies.  
 
1.3.5.4. Syntrophin/dystrophin 
Syntrophins are a family of intracellular adaptors contained in the large 
dystrophin-associated protein complexes (Ou et al. 2003).  Syntrophin 2 has been shown 
to be involved in regulation of Nav1.5 mechanosensitivity and channel kinetics through 
interaction between the PDZ domain of syntrophin 2 and the C-terminus of Nav1.5 (Ou 
et al. 2003).  The increased peak inward sodium current was detected in response to bath 
perfusion, which was used to assess the mechanosensitivity of the sodium channel, 
whereas the perfusion-induced increase in sodium currents was abolished by the 
introduction of a PDZ binding domain containing peptide (Ou et al. 2003).  Co-
transfection of Nav1.5 and syntrophin 2 reduced the availability of sodium channel and 
changed channel activation and inactivation kinetics (Ou et al. 2003).  A recent study 
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suggested that dystrophin together with syntrophin are part of a multiple protein complex 
that modulated the expression level and function of Nav1.5 (Gavillet et al. 2006).   
  
1.4.   Rationale and objectives 
Nav1.5 is a key protein invovled in generation and propagation of the cardiac 
action potential.  Nav1.5 mutations were demonstrated to cause lethal arrhythmias 
including LQTS, Brugada syndrome and PCCD.  However, many questions remained to 
be answered.  First, when this thesis project first began, the only known protein that could 
modulate the function of Nav1.5 was the β1-subunit.  Are there other proteins that can 
interact with and regulate the function of Nav1.5?  Does Nav1.5 function in a large protein 
complex?  Second, the molecular mechanisms by which Nav1.5 mutations cause LQTS 
were not well-defined in vivo.  Do LQTS mutations cause re-modeling of gene expression 
in the heart?  Third, is Nav1.5 expressed in other tissues and does it play a role in other 
tissues or organs?  To address these questions, I initiated three studies.  Thus, this thesis 
covers three interesting areas on Nav1.5.  Chapter II concerns the regulation of Nav1.5 
function. I have identified a new regulatory protein, MOG1, that modulates the function 
of Nav1.5. In Chapter 3, I tested the hypothesis that LQTS mutations cause remodeling of 
gene expression in the heart. Genes whose expression is significantly altered by 
transgenic overexpression of one LQTS mutation in the mouse heart have been identified. 
Studies on Nav1.5 are also expanded into non-cardiac tissues in searching for novel roles 
it may play. Thus, in Chapter 4, I investigated the localization of Nav1.5 in the mouse 
brain to explore the possible novel roles Nav1.5 may play in the brain.  These studies on 
Nav1.5 are expected to help us understand how the function of Nav1.5 is regulated, how 
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Nav1.5 mutations cause life-threatening cardiac diseases and provide insights into the 
pathogenetic molecular mechanism of cardiac arrhythmias.  They will also shed light on 
the new functions that Nav1.5 may play. 
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CHAPTER II. 
 
IDENTIFICATION OF A NOVEL PROTEIN THAT INTERACTS WITH AND 
REGULATES THE FUNCTION OF CARDIAC SODIUM CHANNEL NAV1.5:  
MOG1 INCREASES SODIUM CURRENTS1 
 
 
2.1 ABSTRACT 
       The cardiac sodium channel α subunit Nav1.5 plays an important role in the 
generation and propagation of electrical signals in the heart, and can cause cardiac 
arrhythmias, heart failure and sudden death when mutated or deregulated.  However, the 
precise composition of the multi-protein complex for the channel has not been completely 
defined.  Here we report that the physiological function of Nav1.5 is regulated by MOG1, 
a small protein highly conserved from yeast to humans.  Although MOG1 has been 
implicated in nuclear trafficking of proteins, its localization in cytoplasm and potential 
interaction with a yeast membrane-associated sensor Sln1p suggest that the in vivo 
physiological roles of MOG1 need to be further defined.  Yeast two-hybrid screening 
with the Nav1.5 identified MOG1 as an interactor.  The interaction was confirmed by in 
1Most of the data in this chapter are in press as Wu L et al. (2008) Journal of Biological Chemistry 
283:6968-78.  However this chapter has been rewritten for the purpose of this dissertation. 
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vitro GST pull-down and in vivo co-immunoprecipitation assays.  Co-expression of 
MOG1 with Nav1.5 in HEK293 cells increased sodium current densities, whereas knock-  
down of the expression of MOG1 by siRNA in HEK293 cells with stable expression of   
Nav1.5 revealed a significant reduction of the amplitude or complete abolition of sodium 
currents.  The results were replicated in neonatal mouse ventricular myocytes.  
Immunostaining studies revealed that in the heart, MOG1 was expressed in both atrial 
and ventricular tissues with predominant localization at the intercalated discs.  These 
results indicate that MOG1 is a critical regulator of sodium channel function in the heart 
and reveal a new function for MOG1.  This study further demonstrates the functional 
diversity of Nav1.5-binding proteins, which serve important functions for Nav1.5 under 
different cellular conditions.   
 
 2.2 INTRODUCTION 
       The SCN5A gene encodes Nav1.5, the α-subunit of the cardiac sodium channel 
which plays an important role in generating the cardiac action potential and mediating the 
rapid conduction of electrical impulses through cardiac tissues.  Mutations in the cardiac 
sodium channel have been identified in several important human diseases including long 
QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, cardiac conduction 
defects, and dilated cardiomyopathy associated with atrial fibrillation (Wang et al. 1995, 
Chen et al. 1998, Schott et al. 1999, Tan et al. 2001, Olson et al. 2005).   
    Due to its critical importance in cardiac physiology and human disease, studies to 
define the regulatory proteins and other components of Nav1.5 associated complex have 
been of great interest.  The major component of the sodium channel complex is the pore-
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forming α-subunit that consists of four homologous domains (DI, DII, DIII, and DIV), 
each of which contains six transmembrane segments (S1-S6) (Gellens et al. 1992, Wang 
et al. 1996).  The channel complex contains other subunits, including at least four β-
subunits identified thus far.  Co-expression of the β1-subunit with Nav1.5 caused a small 
but significant acceleration of the recovery from inactivation as well as an increase in 
current density which may be due to an increased targeting efficiency of the mature 
channel to the cell membrane (Nuss et al. 1995, Qu et al. 1995).  The β3 subunit caused a 
depolarizing shift in steady-state inactivation and a slower recovery from inactivation 
than the β1-subunit (Fahmi et al. 2001).  The β2 subunit was shown to cause a 
hyperpolarizing shift in Nav1.5 gating (Johnson et al. 2006).  A mutation in the β4 
subunit was reported to increase the late sodium current associated with long QT 
syndrome (Medeiros-Domingo et al. 2007).     
 In addition to the β subunits, other accessory proteins have been identified for 
Nav1.5. Their interactions have been shown to form a multi-protein complex (Abriel et al., 
2005). Lemaillet et al. demonstrated that a 9-amino acid motif in the cytoplasmic loop II 
conserved through vertebrate sodium channels is responsible for binding to ankyrin G 
and the localization of sodium channel to cell membrane (Lemaillet et al. 2003).  The C-
terminus of Nav1.5 contains 244 amino acid residues that have been shown to be 
important for interactions with proteins such as FHF1B (fibroblast growth factor 
homologous factor 1B), calmodulin (CaM), Nedd4-like ubiquitin-protein ligases, 
syntrophin, Fyn, and protein tyrosine phosphatase (PTPH1) (Abriel H et al. 2005, 
Jespersen T et al. 2006).  In a recent study, 14-3-3 was found to interact with the 
cytoplasmic loop I between DI and DII and its dimerization was needed for regulation of 
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sodium currents (Allouis M et al. 2006).  Despite the diversity in accessory proteins, the 
composition of the cardiac sodium channel complex remains poorly understood.  It is 
reasonable to expect that many more proteins are involved in the dynamic networks of 
protein-protein interactions with Nav1.5 and underscores the significance of multi-protein 
complexes that are critical for normal cardiac function.    
      Finding new Nav1.5-associated proteins in myocyte ionic homeostasis was 
expected to provide an explanation for the disruption of cardiac conduction system that 
leads to arrhythmias and sudden death.  To identify new proteins associated with the 
cardiac sodium channel complex, we performed a yeast two-hybrid screen with separate 
intracellular domains of Nav1.5 as baits.  When the cytoplasmic loop II between DII and 
DIII was used as the bait, a candidate Nav1.5-interacting protein, MOG1, was identified.   
MOG1 was initially identified as a suppressor that was able to rescue the 
temperature-sensitive defect of S. cerevisiae Ran, a protein involved in 
nucleocytoplasmic transport, microtubule and nuclear assembly, and the spatial and 
temporal organization of the eukaryotic cell (Oki et al. 1998, Quimby et al. 2003).  In 
vitro studies showed that MOG1 can bind to Ran-GTP (Oki et al. 1998), and release GTP 
(Steggerda et al. 2000), but its in vivo function is not clear.  MOG1 has been shown to be 
a highly conserved protein from yeast to humans (Marfatia et al. 2001).  Human MOG1 
gene contains 5 exons and 4 introns and encodes a protein of 187 amino acids with a 
calculated molecular weight of 20 kDa (Marfatia et al. 2001).  The highest expression of 
MOG1 was detected in the heart by Northern blot analysis (Marfatia et al. 2001),  
However, the exact physiological function of MOG1 remains to be studied.  Our finding 
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that MOG1 interacts with Nav1.5 suggests that MOG1 may play a role in cardiac 
physiology.   
We further demonstrated the interaction between MOG1 and Nav1.5 by both in 
vitro GST-pull-down and in vivo co-immunoprecipitation assays.  We examined the 
physiological role of MOG1 by co-expression of MOG1 and Nav1.5 in HEK293 cells and 
neonatal cardiomyocytes.  Our results indicate that MOG1 is a co-factor for Nav1.5 and 
modulates the appropriate expression and function of Nav1.5.   
 
2.3  MATERIALS AND METHODS 
Construction of Plasmids and Antibodies  
    The human MOG1 gene was cloned into vector pET28a at the EcoR I and Sal I 
sites (pET28a-MOG1) as previously described (Marfatia et al., 2001).  The MOG1 insert 
was released from pET28a-MOG1 and subcloned into pcDNA3.1C (Invitrogen) at the 
BamH I and Not I sites or into pCMV10, yielding mammalian expression constructs for 
His-tagged MOG1 (pcDNA3.1C-MOG1) and Flag-tagged MOG1 (pCMV10-MOG1), 
respectively.   
     Human cardiac sodium channel gene SCN5A was cloned into vector pcDNA3 
(pcDNA3-Nav1.5) as described (Wan et al., 2000, Wan et al., 2001), and used for 
establishing a stable HEK293 cell line with constant expression of Nav1.5, (hereafter 
referred to as “HEK293/Nav1.5”; a generous gift from Dr. Glenn E. Kirsch).  The 
cytoplasmic loop II (LII) between transmembrane domains DII and DIII of Nav1.5 was 
amplified by PCR using oligos containing Xho I and EcoR I restriction sites (Forward: 5’-
AGAATTCAGCTCCTTC AGTGCAGA-3’, Reverse: 5’-TCTCGAGTTAGTGGT 
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AGCAGGTCTT-3’) and cloned into vector pGEX4T-1-GST-tag (Novagen) (pGEX4T-1-
GST-Nav1.5-LII) for expression and purification of GST-Nav1.5-LII fusion protein.  The 
cytoplasmic loop I (LI) between DI and DII of Nav1.5 was amplified and cloned using an 
identical approach to generate pGEX4T-1-GST-Nav1.5-LI for expression and purification 
of GST-Nav1.5-LI fusion protein.  Primers used to amplify the Nav1.5-LI are 5’-
AGTTCAGGATCCGAGGAGCAAAA-3’ and 5’-CTTACAGCGGCCGCTTACTTCA 
CTCCCT-3’.  Nav1.5-LII was also sub-cloned into pcDNA3.1A to express His-tagged 
Nav1.5-LII (pcDNA3.1A-Nav1.5-LII) in mammalian cells.   
      Two anti-MOG1 antibodies were developed by Genemed Synthesis, Inc.  The 
first MOG1 antibody (#2738) was developed with a MOG1-specific peptide, C-
QPPPDNRSSLGPENL at the N-terminal section, and the immunogen for the second 
antibody (#3350) was a peptide, C-NQQVAKDVTLHQALLRLPQYQTDL at the C-
terminal section.  The rabbit polyclonal anti-Nav1.5 antibody was developed as described 
in chapter IV.   
 
Yeast Two-Hybrid Screen  
      Yeast two-hybrid analysis was performed with a pre-made MATCHMAKER, 
human heart cDNA library constructed in S. cerevisiae host strain, Y187 (ClonTech 
Laboratories, Inc.).  pACT2-derived constructs generate fusion proteins with the GAL4 
activation domain (GAL4 AD) fused to a library of other proteins.  The baits for library 
screening were five different segments of Nav1.5 fused to GAL4-DNA binding domain 
(GAL4 BD) in the pAS2 vector.  As Nav1.5 is a membrane protein, the yeast two-hybrid 
screen with the entire Nav1.5 protein is unlikely to be fruitful because the protein may not 
 37
enter the yeast nuclei.  Thus, we selected five cytoplasmic segments of Nav1.5 as baits.  
These include the N-terminal domain (amino acids 1 to 123), cytoplasmic loop I between 
DI and DII (Nav1.5-LI, amino acids 437 to 711), cytoplasmic loop II between DII and 
DIII (Nav1.5-LII, amino acids 940 to 1200), the inactivation gate between DIII and DIV 
(amino acids 1471 to 1523), and the C-terminal domain (amino acids 1773 to 2016).  A 
bait plasmid was transfected into yeast strain Y187 with a library of human heart cDNAs 
fused to GAL4-AD.  Positive colonies were identified as instructed by the manufacturer 
(ClonTech Laboratories, Inc.).  Approximately 107 primary transformants were screened 
for each of the baits.  DNA was isolated from each positive clone and used to transform E. 
coli HB101 (Leu-) to isolate only pACT2 derivative plasmids.  The cDNA insert from 
each positive pACT2 derivative clone was amplified by PCR and sequenced by the 
BigDye Terminator v1.1 Cycle Sequencing kit and an ABI PRISM 3100 Genetic 
Analyzer.  The DNA sequences were then characterized by Blast analysis against the 
NCBI database to determine the identity of the potential Nav1.5-interacting proteins.   
 
GST Pull-down Assays 
     Construct pGEX4T-1-GST, pGEX4T-1-GST-Nav1.5-LI, or pGEX4T-1-GST-
Nav1.5-LII was transformed into E. coli BL21 to express the GST, GST-Nav1.5-LI, and 
GST-Nav1.5-LII proteins.  The GST and GST-fusion proteins were then affinity-purified 
using glutathione sepharose 4B beads according to the manufacturer’s protocol 
(Amersham Pharmacia Biotech).  The proteins were eluted with 0.01 M glutathione/100 
mM Tris-HCl, pH 7.5, and dialyzed in dialysis buffer (20 mM Tris-HCl, pH 7.5, 50 mM 
NaCl, 0.1 mM EDTA, 20% glycerol, and 0.5 mM DTT).  
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      The [35S]-labeled MOG1 protein was prepared using a TNT Quick Coupled 
Transcription/Translation system (Promega).  Briefly, 1 µg of plasmid DNA was mixed 
with TNT Quick Master mix and [35S]-methionine, and incubated for 90 minutes at 30°C.  
The [35S]-labeled MOG1 protein was mixed with GST, GST-Nav1.5-LI, or GST-Nav1.5-
LII immobilized on glutathione sephrose 4B beads in binding buffer (1 mM DTT, 0.5 
mM PMSF, 1 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl, 0.1% Triton X-100), and 
incubated for 2-3 hours at 4°C.  After binding, the beads were washed with binding buffer, 
and bound proteins were eluted with 1X SDS loading buffer, separated on a 12% SDS-
polyacrylamide gel, dried, and visualized by exposing to X-ray film at -80°C for 12 hours.   
 
Co-Immunoprecipitation (co-IP) Analysis  
      HEK293/Nav1.5 cells were maintained in Dulbecco’s minimum essential medium 
(DMEM) supplemented with 10% heat inactivated fetal bovine serum (Invitrogen) and 
transfected with 10 µg of pcDNA3.1C-MOG1 DNA for the expression of His-tagged 
MOG1 with Lipofectamine 2000 (Invitrogen).  Transfection was carried out with 80% 
confluent cells in a 10 cm plate.   Harvested HEK293 cells/cardiomyocytes were lysed in 
the TNEN buffer (50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2.0 mM EDTA, 1.0% 
Nonidet P40, protease inhibitor cocktail (Roche Molecular Biochemicals Complete 
Solution) for 24 to 48 hours after transfection.  500 µg of total cell extracts was mixed 
with a rabbit polyclonal anti-Nav1.5 antibody (Wu et al., 2002) and incubated on a rotator 
for 3 hours at 4°C.  Protein A/G sepharose 4B beads (Sigma-Aldrich) were added and 
incubation was continued for another 2 hours.  The bound proteins were eluted by boiling 
the samples for 5 minutes in 1X SDS loading buffer, separated by SDS-PAGE, and 
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transferred onto a nitrocellulose membrane.  The membrane was probed with an anti-His 
antibody (Sigma-Aldrich) recognizing His-MOG1 fusion protein, and the protein signal 
was visualized by enhanced chemiluminescence according to the manufacturer's 
instructions (Amersham Biosciences).  For reverse co-IP, a rabbit polyclonal anti-MOG1 
antibody was used for immunoprecipitation and the anti-Nav1.5 antibody was used for 
Western blot analysis.  Similar co-IP studies were performed to study the interaction 
between the cytoplasmic loop II of Nav1.5 and MOG1 by co-expressing His-tagged 
Nav1.5-LII and Flag-tagged MOG1 in HEK293 cells and with an anti-His antibody and 
an anti-Flag antibody.   
For co-immunoprecipitation analysis of MOG1 and Nav1.5 in cardiac cells, total 
protein lysates were isolated from adult mouse hearts.  Mice were sacrificed and the 
hearts were excised, washed in Hanks buffer, cut into pieces, add lysed in the lysis buffer 
(20 mM Tris-HCl, pH7.4, 1 mM EDTA, 150 mM NaCl, 1% NP-40, cocktail of protease 
inhibitors).  The lysates were sonicated on ice (Sonicator 3000, Misonic Inc, NY), 
incubated on ice for 30 min, and then microcentrifuged at 40C for 10 min.  The 
supernatant was collected and its concentration was measured using the BioRad Protein 
Assay dye.  The lysates were pre-cleared on protein A/G beads at 4 °C for 40 min prior to 
co-IP studies.  Protein A/G beads (40 µl) were incubated with 2 µg of the anti-Nav1.5 (or 
anti-MOG1) (1:500 dilution in PBST) and 500 µg of cell lysates with gentle rocking for 2 
h at 4 °C.  After washing five times with washing buffer (PBS buffer, protease inhibitors, 
and 0.5% Triton X-100), the immunoprecipitates were subjected to SDS-PAGE and 
immunoblot analysis using the anti-MOG1 antibody (or anti-Nav1.5).  Cell lysates 
incubated with protein A/G beads alone were used as a negative control.  Co-IP of lysates 
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with normal IgG was also used as a negative control in each experiment. Studies were 
repeated at least three times.    
 
Isolation of Mouse Cardiomyocytes  
      For isolation of neonatal mouse cardiomyocytes, 10-15 mouse hearts were 
collected from 3-day-old CBA/B6 mouse neonates.  The ventricles were excised and 
myocytes were isolated using the Neonal Rat/Mouse Cardiomyocyte Isolation kit from 
CELLUTRON Life Technology.  The cells were plated on uncoated 100 mm plates to 
reduce the contamination of cardiac fibroblasts.  Myocytes were then cultured in the NS 
medium (CELLUTRON Life Technology) supplemented with 10% FBS.  Isolation of 
adult cardiomyocytes was performed as previously described by us (Tian et al., 2004, 
Yong et al., 2006, Yong et al., 2007).  The heart was isolated from a mouse (6-8 months) 
and mounted on a Langendorff apparatus for retrograde perfusion in calcium-containing 
buffer (in mM): 118, CaCl2; 2.5 MgCl2; NaCl; 4.8, KCl; 2, 1.2 KH2PO4; 11, glucose; 
13.8, NaHCO3; 4.9, pyruvic acid; pH 7.2–7.4, with 95% O2:5% CO2; at 37 °C.  The 
calcium free buffer was then replaced and 0.5 mg/ml collagenase was added for digestion 
(Type II, Worthington).  After 30 minutes of digestion, cells were collected for further 
studies. 
 
Immunohistochemistry  
Immunostaining was performed on adult cardiomyocytes or frozen heart sections (6 µm) 
with polyclonal anti-Nav1.5 and anti-MOG1 antibodies.  Briefly, a freshly excised mouse 
heart was embedded in Tissue-TEK O.C.D. Compound (Ted Pella, Inc.CA) and frozen in 
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liquid nitrogen.  The frozen sections were pretreated with hydrogen peroxide.  The 
cardiomyocytes were pretreated with 2% Triton-X100.  The pretreated section or the 
cardiomyocytes were then blocked in blocking buffer (5% bovine serum albumin and 
0.3% Triton X-100 in 1x PBS) for 2 hr, and then incubated with the primary antibody 
(1:250 dilution) at 4°C for 24 hours.  The sections were then incubated with a secondary 
antibody mixture containing the FITC-conjugated and Texas Red-conjugated secondary 
antibodies at room temperature for 2 hours.  The immunostained slides were mounted 
with anti-fading media, and visualized under a confocal microscope. 
 
RNA Interference Analysis   
      MOG1-specific siRNAs were synthesized by Dharmacon RNA Technologies.  
Two siRNAs were targeted to mouse MOG1 and their sequences were: siRNA1, 5’-
GAGCCUGAGUAACUUUGAAdTdT-3’ and siRNA2, 5’-UAACUAGUUUGACU 
CUUCAdTdT-3’.  Blast analysis against the NCBI database suggests that the two 
siRNAs are specific to MOG1 and do not match any other genes in the mouse genome.  
The control scrambled siRNA sequences were selected by GenScrip.  The sequences for 
scrambler siRNAs were 5’-UCAUGCCAUUCUUAGUAAU dTdT-3’ for siRNA1, and 
5’-CGAUAGU TTCTUGUCTGGAdTdT-3’ for siRNA2.  The siRNAs were labeled with 
fluorescein at the 5’-end.  The siRNAs were transfected into cells by oligofectamine 
(Invitrogen).  Cells were incubated for another 48 hours for expression and functional 
studies.  
 
Quantitative Real-Time (RT)-PCR Analysis 
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      Total RNA was isolated from siRNA-treated cells using TRIzol reagent 
(Invitrogen).  Reverse transcription was performed using the SuperScript Choice System 
(Invitrogen).  Quantitative RT-PCR was performed with SYBR Green (Applied 
Biosystems) with an ABI Prism 7900HT Sequence Detection System.  18S rRNA was 
used as an internal control.  The relative mRNA expression level of MOG1 was indirectly 
shown as CT values (threshold cycle or the fractional cycle number at which the amount 
of amplified target reaches a fixed threshold).  The CT values were then normalized by 
the RT program as previously described (Tan et al. 2002).  Briefly, the target PCR CT 
value subtracts 18S PCR CT value to yield the ∆CT value, and this value is then adjusted 
to the mean ∆CT value of untreated cells, generating the ∆∆CT value.  The relative 
mRNA expression level for each sample was then calculated using the following equation: 
relative mRNA expression = 2-∆∆CT (Tan et al. 2002).   
 
Electrophysiological Analysis  
      HEK293/Nav1.5 cells or neonatal cardiomyocytes were transfected with 
pcDNA3.1C-MOG1 using Lipofectamine 2000 (Invitrogen) and electrophysiological 
recordings were performed as described previously (Tian et al., 2004, Yong et al., 2007).  
Vector pIRE-GFP DNA expressing green fluorescent GFP protein (0.25 µg) was co-
transfected together with pcDNA3.1C-MOG1 to serve as an indicator (Wan et al., 2001, 
Wu et al. 2002).  Only GFP-positive cells were selected for recording sodium currents.  
Cells with successful transfection of siRNAs were also identified by the green color as 
the siRNAs were labeled with fluorescence at the 5’-end.  Pipettes were fabricated from 
boroscillate glass (FHC, Inc.) and electrode resistance ranged from 2-3 MΩ when filled 
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with pipette solution with the following composition (in mM): NaCl, 20; CsCl, 130; 
HEPES, 10; EGTA, 10; pH 7.2 with CsOH.  Voltage command pulses were generated 
using the Multipatch 700B amplifier (Axon Instruments) under the control of a desktop 
computer with pCLAMP software (9.0, Axon Instruments).  Currents were filtered at 5 
kHz (-3 dB, 4-pole Bessel filter) following series resistance compensation.  The holding 
potential for all pulse protocols was -100 mV and experiments were performed at room 
temperature (22°C).  For HEK293 cells, the composition of the bath solution was (in 
mM): NaCl, 70; CsCl, 80; KCl, 5.4; CaCl2, 2; MgCl2, 1; HEPES, 10; glucose, 10; pH 7.3 
with CsOH.  For neonatal cells, the NaCl concentration was reduced to 20 mM and CsCl 
was increased to 120 mM for better voltage control.  To reduce contaminating Ca2+ and 
K+ (transient outward) currents, 2 mM CdCl2 and 2 mM 4-AP, respectively, were added 
to the bath.  
 
Western blot analysis 
To determine the expression level of the Nav1.5 protein in the membrane fraction, 
total protein lysates were extracted from HEK293/Nav1.5 cells transiently transfected 
with pcDNA3.1C-MOG1 or empty vector pcDNA3.1C as control using the lysis buffer 
(1% Triton-100, 150 mM NaCl, 50 mM Tris-HCl, pH7.5, 1 mM EDTA, a protease 
inhibitor cocktail).  Membrane fractions were isolated by centrifugation at 40,000 rpm 
followed by another centrifugation at 14,000 rpm.  The final pellet contains the 
membrane protein fraction and the supernatant contains the cytosolic protein fraction.  
Equal amounts of protein extracts were separated on SDS-PAGE.  Western blot analysis 
was performed as described previously (22).  A rabbit polyclonal anti–Nav1.5 was diluted 
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in 1:500 in 0.3% BSA in PBST, and used in Western blot analysis.  The signal was 
detected using enhanced chemiluminescence (ECL kit, Amersham Biosciences, 
Buckinghamshire,UK).  An anti-KCNQ1 antibody (Santa Cruz Biotechnology) was used 
as a loading control at 1:500 dilution in PBST. 
Statistical Analysis 
      Data are represented as mean values ± SEM.  Statistical analysis was performed 
using an ANOVA and two-tailed Student’s t-test to compare means.  Significance was set 
at the indicated P values. 
 
2.4  RESULTS 
 
MOG1 was identified as a candidate protein that interacts with Nav1.5 by a yeast 
two-hybrid screen  
     To identify proteins that interact with Nav1.5, we carried out a yeast two-hybrid 
screen.  We screened a human cardiac pre-transformed MATCHMAKER cDNA library 
(ClonTech, Inc.).  Five cytoplasmic segments of Nav1.5 were used as baits for the 
screening and these include the N-terminus, loop I (between DI-DII), loop II (between 
DII–DIII), loop III (between DIII–DIV), and C-terminus.  The Nav1.5 C-terminus-GAL4-
BD fusion protein alone activated transcription of reporter genes, thus no further 
screening was performed with this bait.  No positive clones were obtained with the N-
terminal domain and cytoplasmic loop I baits.  There were 223 positive clones obtained 
with the cytoplasmic loop II bait, and 29 positive clones with the loop III bait (Appendix 
B).  One positive clone from the screening was found to encode the portion of MOG1 
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(GenBank Accession# AF265206, amino acids 65 to 186), and was independently 
identified twice from the library screening. 
 
Interaction between MOG1 and Nav1.5 as shown by GST pull-down 
      To further evaluate the interaction between MOG1 and Nav1.5, we carried out a 
GST pull-down assay.  The cytoplasmic loop II of Nav1.5 (amino acids 940 to 1200) was 
fused to GST (GST-Nav1.5-LII), expressed in E. coli, and purified.  Radioactively-
labeled MOG1 protein was prepared by in vitro transcription followed by translation 
using 35S-methionine and this appeared as a single band of 28 kDa (Fig. 2.1A, lane 1).  
The GST-Nav1.5-LII fusion protein successfully pulled down 35S-MOG1 in the assay 
(Fig. 1A, lane 2), whereas two negative controls, GST alone (Fig. 2.1A, lane 4) and the 
GST-Nav1.5 cytoplasmic loop I fusion protein (GST-Nav1.5-LI, Fig. 2.1A, and lane 3) 
failed to interact with 35S-MOG1.  These results suggest that MOG1 interacts with the 
cytoplasmic loop II of Nav1.5 in vitro.   
 
Interaction between MOG1 and Nav1.5 as shown by co-immunoprecipitation 
      HEK293/Nav1.5 was transfected with pcDNA3.1C-His-MOG1.  Cell extracts 
were immunoprecipitated using an antibody against MOG1 (Fig. 2.2A, lane 3) or with 
control rabbit pre-serum IgG (Fig. 2.2A, lane 2).  The bound proteins were then detected 
by Western blot analysis with an anti-Nav1.5 antibody.  The anti-MOG1 antibody, but not 
the control IgG, precipitated a 250 kDa Nav1.5 protein.  Reciprocal co-
immunoprecipitation was also performed.  The anti-Nav1.5 antibody was used for 
immunoprecipitation, and the anti-MOG1 antibody was used for Western blot analysis.  
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MOG1 protein was successfully precipitated by the anti-Nav1.5 antibody, but not by the 
rabbit pre-serum control (Fig. 2.2B).  The interaction between Nav1.5 and MOG1 was 
also evaluated in cardiomyocytes.  Nav1.5 was immunoprecipitated by an anti-MOG1 
antibody (Fig. 2.2E) and MOG1 was precipitated by an anti-Nav1.5 antibody (Fig. 2.2F).  
These results support the interaction between MOG1 and Nav1.5.  
The interaction between MOG1 and Nav1.5 was further confirmed in mouse 
cardiac cells.  Total protein extracts were prepared from mouse hearts.  Both MOG1 and 
Nav1.5 proteins are abundantly expressed in cardiac cells, and can be easily detected by 
Western blot analysis (lanes 1 in Fig. 2E and lane 1 in Fig 2F).  Two protein bands were 
detected for MOG1, which may represent the two MOG1 isoforms derived from 
alternatively spliced transcripts as reported previously by Marfatia et al (Marfatia et al 
2001).  Mouse cardiac protein extracts were precipitated either with a polyclonal 
antibody against MOG1 (Fig. 2E, lane 2) or with control IgG (Fig. 2E, lane 3).  The 
bound proteins were then detected by immunoblot analysis with an anti-Nav1.5 antibody.  
The MOG1 antibody easily precipitated a Nav1.5 protein (Fig. 2E, lane 2).  Similar 
experiments revealed that the anti Nav1.5 antibody could precipitate MOG1 proteins from 
mouse cardiac cell extracts (Fig. 2E, lane 2).  These results indicate that MOG1 interacts 
with Nav1.5 in vivo in cardiac cells.   
     As MOG1 was pulled out from the yeast two-hybrid library using Nav1.5-LII, we 
next determined whether the loop II interacts with MOG1 using the co-
immunoprecipitation assay.  HEK293 cells were transiently co-transfected with   
 
 
 
 
 47
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1.  GST pull-down assay for the interaction between Nav1.5 and MOG1. A). 
Coommassie staining for purified GST and GST fusion proteins.  B). In vitro-translated 
35S-MOG1 bound strongly to Nav1.5 cytoplasmic loop II fused to GST (GST-Nav1.5-LII; 
lane 2), but not to cytoplasmic loop I fused to GST (GST-Nav1.5-LI; lane 3) or GST 
alone (lane 4).  Lane 1, one-tenth of the input (35S-MOG1). 
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Fig. 2.2.  Co-immunoprecipitation assay for the interaction between Nav1.5 and 
MOG1.  A, Whole cell lysates prepared from HEK293/Nav1.5 cells transiently 
transfected with a pCMV-10-MOG1 construct were immunoprecipitated with an anti-
MOG1 antibody (lane 3) or pre-serum (lane 2) and analyzed by Western blotting with a 
polyclonal anti-Nav1.5 antibody.  The anti-MOG1 antibody successfully precipitated 
Nav1.5.  Lane1, one-tenth of the input (cell extracts). B, Reciprocal co-
immunoprecipitation with an anti-Nav1.5 antibody for immunoprecipitation and the anti-
MOG1 antibody for Western blotting.  Lane 3, one-tenth of the input (cell extracts).  C, 
Interaction between His-tagged loop II of Nav1.5 and Flag-tagged MOG1 co-transfected 
into HEK293 cells.  An anti-His antibody successfully precipitated Flag-tagged MOG1 
(lane 2), but the control mouse serum failed to precipitate Flag-tagged MOG1.  Lane 1, 
1/50 of the input (cell extracts).  D, Reciprocal co-immunoprecipitation for C. Lane 1, 
control mouse serum failed to precipitate His-tagged Nav1.5-LII; lane 2, an anti-Flag 
antibody successfully precipitated His-tagged Nav1.5-LII; lane 3, 1/50 of the input (cell 
extracts).  E. Protein lysates extracted from mice cardiac cells were immunoprecipitated 
with an anti-MOG1 antibody (lane2) and control serum (lane3).  Lane 1, one-fifth of 
input. Signals were detected with an anti-Nav1.5 antibody. F. Reciprocal co-
immunoprecipitation with an anti-Nav1.5 antibody for immunoprecipitation and the anti-
MOG1 antibody for Western blotting.  Lane 1, one-fifth of input.  Lane 2, 
immunoprecipitation with anti-Nav1.5.  Lane 3, immunoprecipitation with control serum. 
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LII (pcDNA3.1A-Nav1.5-LII).  Cell extracts were immunoprecipitated using a 
monoclonal antibody against His or with control IgG.  The bound proteins were then 
detected by Western blot analysis with a monoclonal anti-Flag antibody.  The anti-His 
antibody, but not the control IgG, precipitated Flag-tagged MOG1 (Fig. 2.2C).  A co-
immunoprecipitation assay was performed using an anti-Flag antibody for 
immunoprecipitation.  Nav1.5-LII fusion protein was successfully precipitated by the 
anti-Flag antibody, but not by control mouse serum IgG (Fig. 2.2D).  These 
coimmunoprecipitation results indicate that the association of MOG1 to Nav1.5 is 
mediated by the cytoplasmic loop II of Nav1.5.   
 
MOG1 increases sodium current density in a mammalian expression system   
      We wished to determine whether the interaction of MOG1 with Nav1.5 modified 
channel function.  For this purpose, we expressed MOG1 in HEK293/Nav1.5 cells and 
measured whole-cell sodium currents.  As shown in Fig. 2.3A and 2.3B, the sodium 
current density (expressed as peak current normalized to cell capacitance, pA/pF) across 
the range of test potentials was significantly increased in cells co-expressed with MOG1.  
The maximum current density normally measured at -30 mV for vector cells was shifted 
to -35 mV and increased by 61 pA/pF when co-expressed with MOG1.  This is despite 
the fact that co-expression with MOG1 did not alter cell capacitance (16.6 ± 4.1 pF, n = 5 
versus 18.6 ± 1.9 pF, n = 9).  Steady-state activation and inactivation gating properties 
were evaluated using the pulse protocols shown in the insets (Fig. 2.3C).  The data for 
channel activation are the mean normalized conductance plotted against the test potential.  
MOG1 shifted the voltage dependence of activation to more negative potentials by 4 mV 
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Fig. 2.3.  Over-expression of MOG1 in HEK293/Nav1.5 cells increased sodium 
current density. A, Raw traces for sodium currents with (right) and without (left) over-
expression of MOG1 that were elicited with the current protocol depicted in the inset.  B, 
For activation, cells were held at -100 mV and depolarized in 5 mV increments.  The 
current-voltage relationship for both cell groups is summarized with current amplitudes 
normalized to cell capacitance (pA/pF, abscissa).  Both steady-state activation and 
inactivation were determined by fitting the peak currents with a Boltzman distribution: 
I/Imax = 1/(1+e((-V-V1/2)/s)), where I is the current at test potential V, Imax is the 
maximum current, V1/2 is the potential giving the half-maximum current; see Text for 
fitting parameters.  C, Steady-state activation (right) and inactivation curves (left).  
Steady-state activation was plotted over the indicated voltage range and expressed as the 
current at the test potential over the maximum current (I/Imax, abscissa).  A two-pulse 
protocol was used to estimate the membrane potential dependence of inactivation.  Cells 
were stepped to conditioning potentials for 500 ms as shown on the abscissa before 
depolarization to -20 mV (50 ms step) and peak sodium current from the test potential 
was normalized to peak sodium current in the absence of a conditioning step.  D, 
Recovery from inactivation was assessed for both cell groups utilizing a two-pulse 
protocol and the fractional current (P2/P1) was plotted against inter-pulse duration 
between P1 and P2.  The fraction of channels that had recovered following various time 
intervals was calculated by dividing the peak current measured during a test pulse to -20 
mV.  The average data were fitted with a bi-exponential function: I/Imax = A1x(1-e(-
t/τ1))+A2x(1-e(-t/τ2)).  In cells over-expressing MOG1, no effects in the inactivation 
kinetics were observed but a hyperpolarizing 4 mV shift was detected in channel 
activation. 
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(V1/2act = -49.1 ± 0.1 mV, n = 5 versus -45.1 ± 0.2 mV, n = 9, P<0.05).  A two-pulse 
protocol was used to estimate the membrane potential dependence of inactivation.  Cells 
were stepped to conditioning potentials for 500 ms as shown on the abscissa before 
depolarization to -20 mV (50 ms step) and the peak current from the test potential was 
normalized to peak sodium current in the absence of a conditioning step.  Cells 
expressing MOG1 showed no difference in the inactivation kinetics of Nav1.5 (Fig. 2.3C; 
V1/2inact = -84.1 ± 0.1 mV, n = 5 versus -85.5 ± 0.1 mV, n = 7, P = NS).  Similarly, 
recovery from inactivation was not changed (Fig. 3D; t1/2 (τ1) = 4.2 ± 0.2 ms, n = 5 versus 
3.8 ± 0.1 ms, n = 6, P = NS) as this was assessed using a two-pulse protocol and the 
fractional current (P2/P1) was plotted against inter-pulse duration between P1 and P2.  
These results show that MOG1 regulates the function of Nav1.5 by increasing sodium 
current density and by modulating channel activation kinetics with a small 
hyperpolarizing shift.   
 
Knockdown of MOG1 Expression Reduced Sodium Current Density in a 
Mammalian Expression System 
      Two MOG1-specific siRNAs were transfected into HEK293/Nav1.5 cells with 
expression of MOG1.  As shown in Fig. 2.4, Western blot analysis revealed that the 
siRNAs were effective in knocking down MOG1 expression by around 80% compared to 
cells treated with scramble siRNAs (18S rRNA was used as an internal control in these 
experiments).  The knockdown of MOG1 expression was further confirmed with 
quantitative RT-PCR analysis (data not shown).  Sodium current density was reduced by 
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Fig. 2.4.  Effects of siRNAs on expression of MOG1.  A, Knockdown of MOG1 
expression was determined by Western blot analysis (β-actin as loading control).  B, The 
image from Western blot analysis was quantified and plotted.  Two siRNAs and 
corresponding scrambles were tested.  siRNA1 and siRNA2 knocked down expression of 
MOG1 by 4.2-fold and 3.9-fold, respectively. 
 
 
 
 
 
 
 
 55
nearly 2-fold in siRNA-transfected HEK293/Nav1.5 cells (Fig. 2.5A, 2.5B) with no 
alterations in the activation and inactivation kinetics (Fig. 2.5C, 2.5D).  Cell capacitances 
were no different between cell groups, 15.7 ± 1.3 pF (MOG1- siRNA) and 18.2 ± 1.4 pF 
(scramble), P = NS.  The kinetic parameters are as follows for MOG-siRNA versus 
scramble: V1/2act = -46.3 ± 0.4 mV, n = 6 versus -49.3 ± 0.2 mV, n = 5, P = NS; V1/2inact = 
-83.4 ± 0.2 mV, n = 6 versus -81.7 ± 0.2 mV, n = 5, P = NS; and t1/2 (τ1) = 7.1 ± 0.2 ms, n 
= 6 versus 7.6 ± 0.3 ms, n = 5, P = NS.  Therefore, reducing the endogenous expression 
of MOG1 decreases sodium currents and suggests that MOG1 is required for the full 
activity of cardiac sodium channels. 
 
MOG1 and Sodium Current Density in Neonatal Cardiomyocytes   
      To determine the role of MOG1 in native cardiomyocytes, we studied the effects 
of MOG1 on the function of Nav1.5 in neonatal mouse cardiomyocytes as in 
HEK293/Nav1.5 cells.  When MOG1 was over-expressed in 3-day neonatal myocytes, 
sodium current density was increased by two-fold compared to control vector-transfected 
myocytes with no apparent changes in cell capacitances (Fig. 2.6).  Sodium currents were 
elicited using a single pulse from -100 to -20 mV.  Knockdown of MOG1 expression 
with siRNAs in neonatal cells nearly eliminated the sodium currents (Fig. 2.7), while no 
effects on the current were detected following transfection with siRNA scrambles 1 and 2.  
These results show that in native cardiomyocytes, MOG1 exhibits a similar and 
significant regulatory role on cardiac sodium channels as in HEK293 cells. 
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Fig. 2.5.  Knockdown of MOG1 expression by siRNAs in HEK293/Nav1.5 cells 
decreased sodium current density.  A, Raw traces of sodium currents in cells 
transfected with a scramble (left) and a MOG1-specific siRNA1 (right).  B, Effects of 
MOG1-specific siRNA1 and control scramble siRNA on the current-voltage relationship 
of Nav1.5.  Identical results were obtained for siRNA2 (data not shown).  C, D, The effect 
of MOG1-specific siRNA1 on steady-state activation, inactivation, and recovery from 
inactivation, respectively, was evaluated.  The sodium currents were recorded and 
analyzed as described in the Legend of Fig. 3. 
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Fig. 2.6.  MOG1 over-expression increases sodium current densities in neonatal 
cardiomyocytes.  Maximum currents were elicited using a single pulse from -100 to -20 
mV and peak currents were expressed as current densities (pA/pF) and averaged for the 
cell group.  Cell capacitances (Cm) = 32.2 ± 4.7 pF (+ MOG1), 29.3 ± 2.8 pF (-MOG1).  
“*” indicates P=1.5x10-5. 
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Fig. 2.7.  Effects of MOG1 siRNAs on sodium current densities in neonatal 
cardiomyocytes.  Maximum currents were elicited using a single pulse from -100 to -20 
mV and peak currents were expressed as current densities (pA/pF) and averaged for the 
cell group.  Cm = 27.3 ± 3.1 pF (siRNA1), 30.4 ± 4.0 pF (siRNA2), 29.3 ± 3.1 pF 
(scramble 1), 32.3 ± 2.2 pF (scramble 2).  “*” indicates P=2.2x10-6, whereas “**” 
indicates P=2.5x10-5. 
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Strong expression of MOG1 at intercalated discs in cardiomyocytes and heart 
tissues      
The expression patterns of MOG1 in the heart was studied using immunostaining 
with two independent anti-MOG1 antibodies.  Peptide competition experiment was used 
to evaluate the specifity of antibody.  Immunofluorescent signal was significantly 
eliminated when the MOG1 antibody (with MOG1 antibody #2728) was pre-absorbed 
with the antigen peptide (Fig. 2.8A and 2.8B).  As shown in Fig. 2.8C, MOG1 was 
widely expressed in both atrial and ventricular muscles (with MOG1 antibody #2728) and, 
interestingly, this expression was highly localized in the intercalated discs.  Similar 
results were obtained with the second anti-MOG1 antibody (#3350; data not shown).  
Immunostaining with a connexin 43 antibody made it possible to easily distinguish the 
AV node from atrial and ventricular tissues (Fig. 2.8D).  Similar to connexin 43, 
expression of MOG1 protein was high in atrial and ventricular tissues but low in AV 
nodal tissues.  Immunostaining studies were also performed in isolated mouse ventricular 
myocytes and the results show that MOG1 expression was also particularly strong in the 
intercalated discs.  More importantly, the expression pattern of MOG1 was shown to 
overlap with that of Nav1.5 in intercalated discs (Fig. 2.8E). 
 
MOG1 Increases Cell Surface Expression of Nav1.5.   
To investigate the potential mechanism by which MOG1 increases the sodium 
channel density, Western blot analysis was performed with the membrane fraction and 
cytoplasmic fraction of protein extracts isolated from HEK293/Nav1.5 cells transiently 
transfected with MOG1 or empty vector (control).  As shown in Fig 2.9A, Nav1.5     
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Fig. 2.8.  Expression profile of MOG1 protein in heart tissues and isolated 
ventricular myocytes.  MOG1 antibody specificity was examined in two adjacent tissue 
slides (A and B).  Atrial muscle was immunostained by an anti-MOG1 antibody (A) or 
the MOG1 antibody preincubated with the peptide immunogen (B). scale bar=100 µm. C, 
Strong expression of MOG1 in right atrium (RA) and right ventricle (RV) with relatively 
lower expression in the distal common bundle or atrio-ventricular node (AV).  D, 
Immunostaining showing expression profile of connexin 43 (CX43). Scale bar=100 µm  
E, Co-localization of MOG1 and Nav1.5 at intercalated discs in a cardiomyocyte.  Adult 
ventricular myocytes were isolated and double-stained with polyclonal anti-MOG1 (red) 
and anti-Nav1.5 (green) antibodies.  Nuclei were stained with DAPI (blue).  Right panel 
indicates the overlay of MOG1 and Nav1.5 images. Scale bar=10µm. 
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Fig. 2.9.  Co-expression of MOG1 increased cell surface expression of Nav1.5.  A, 
Western blot analysis with an anti-Nav1.5 antibody with the membrane fraction of protein 
extracts from HEK293/Nav1.5 cells transfected with a MOG1 expression plasmid (+) or 
the empty control vector (-).  The membrane filter was later immunoblotted with an anti-
KCNQ1 antibody to ensure that an equal amount of proteins extracts were used in the 
study.  Overexpression of MOG1 increased the expression of Nav1.5 on cell membrane.  
B, Similar studies as in (A), but the cytosolic fraction of protein extracts was analyzed.   
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expression in the membrane fraction was increased with overexpression of MOG1 in 
comparison with the control.  Accordingly, Nav1.5 expression in the cytoplasmic fraction 
was reduced with overexpression of MOG1 (Fig. 2.9B).  These results suggest that 
MOG1 increases cell surface expression of Nav1.5, which is consistent with the result 
that co-expression of MOG 1 and Nav1.5 increased sodium channel densities (Fig. 2.3 
and Fig. 2.6).   
 
2.5  DISCUSSION 
 Here we report a new interacting protein for the cardiac sodium channel Nav1.5 
and its effects on the activity of the cardiac sodium currents.  Using a yeast two-hybrid 
screen, we identified MOG1 as a candidate protein that interacted with the cytoplasmic 
loop II of Nav1.5.  In vitro GST pull-down analysis showed interaction of MOG1 with 
loop II, but not with the loop I between domains I and II.  These results suggest that the 
loop II of Nav1.5 is the domain that interacts with MOG1.  Both in vitro GST pull-down 
and in vivo co-immunoprecipitation analyses further demonstrated this interaction.  Over-
expression of MOG1 in both HEK293/Nav1.5 cells and neonatal cardiomyocytes resulted 
in increased whole-cell sodium current density, whereas knockdown of MOG1 
expression dramatically reduced or eliminated sodium currents.  Our results reveal a new 
role for MOG1 and suggest that this small protein is a critical component in the multi-
protein complex of the cardiac sodium channel with a strong modulatory effect on Nav1.5.   
 Increased sodium current densities in HEK293/Nav1.5 cells caused by the over-
expression of MOG1 suggest that there is either an increase in the number of sodium 
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channels on the cell surface or an enhancement in single channel conductance.  Kinetic 
analysis of the steady-state activation and inactivation kinetics of Nav1.5 in 
HEK293/Nav1.5 cells over-expressed with MOG1 revealed a small 4 mV hyperpolarizing 
shift in activation with little or no effects on channel inactivation.  This, by itself, does 
not come close to accounting for the increase (~60 pF/pA) in the current density in 
HEK293/Nav1.5 cells with overexpression of MOG1.  Following examinations of excised 
patches from HEK293/Nav1.5 cells over-expressed with MOG1, we further revealed no 
effect on single channel conductance (data not shown).  These results prompted us to 
examine the possibility that an increase in the number of sodium channels on the cell 
surface may be the underlying mechanism for the finding of increased sodium current 
densities by MOG1.  This hypothesis was tested by Western blot analysis, which revealed 
an increase of Nav1.5 expression in the plasma membrane (Fig 2.9A), and a decrease of 
Nav1.5 expression in the cytoplasm of HEK293/Nav1.5 cells over-expressed with MOG1 
(Fig 2.9B).  Taken together, the available evidence supports a model in which MOG1 
increases the number of sodium channel and/or availability on cell surface, which then 
results in an increase in sodium current density.   
      The exact physiological role of MOG1 was previously unknown.  The only 
function of MOG1 reported to date is to form a complex with Ran (Oki et al. 1998).  The 
hypothesized roles of hMOG1 for facilitating the release of GTP and for promoting 
nueclar transport of other proteins remain to be determined.  Expression of MOG1 has 
been demonstrated in both the nucleus and cytoplasm.  One function of cytoplasmic 
MOG1 may be to regulate the function of Nav1.5.  This hypothesis is further supported 
by the finding that MOG1 is highly expressed in intercalated disks of heart as Nav1.5 
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does, which suggests that it plays a very important role in the cardiac cells.  Northern blot 
analysis revealed that the heart was the tissue with the highest expression level of MOG1 
(Marfatia KA et al. 2001).  In this study, we studied the expression of MOG1 in the 
mouse heart at the protein level using two independent antibodies that were specific to 
MOG1.  Our immunostaining results revealed that the expression of MOG1 protein was 
specifically high in both atrial and ventricular tissues compared to the AV node (Fig. 
2.8C).  Interestingly, the protein expression of MOG1 was highly localized at the 
intercalated discs or the cell-to-cell junctions.  The expression pattern of MOG1 was 
similar to the pattern shown by connexin 43, the primary gap junctional protein in cardiac 
myocytes, whereby the expression was localized to the intercalated discs of both the 
atrium and ventricular sections (Fig. 2.8D).  As intercalated discs are essential for 
regulating electrical coupling between cells in the myocardium, co-localization of MOG1 
and Nav1.5 in these regions suggests that MOG1 may play an important role in 
establishing and regulating electrical connections between cardiomyocytes. 
MOG1 is highly conserved from yeast to humans, suggesting that it is an essential 
protein for cellular functions.  However, the specific physiological function(s) of MOG1 
is obscure.  MOG1 was shown to interact with Ran GTPase, a protein is required for the 
trafficking of proteins and RNA in and out of the nucleus, and mediates the release of 
GTP from Ran in vitro (Oki et al.1998, Quimby et al. 2003).  Thus, MOG1 was proposed 
to play a regulatory role in nuclear import and export by maintaining the Ran-GTP 
gradient from the nuclei to the cytoplasm (Steggerda et al. 2000).  During the 
nucleocytoplasmic transport, MOG1 was proposed to shuttle between the cytoplasm and 
the nucleus (Steggerda et al. 2000).  Indeed, in HEK293 cells, human MOG1 is localized 
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throughout the cell (Marfatia et al. 2001).  Due to its cytoplasmic localization, the 
function of MOG1 may not be restricted to the nucleus, on the contrary, it may function 
outside of the nucleus.  A research group showed that yeast MOG1 may interact with an 
osmotic stress sensor Sln1p and regulates the SLN1-SKN7 signal transduction in yeast 
(Lu et al. 2004).  It is interesting to note that Sln1p is a plasma membrane protein, 
specifically a two-transmembrane domain sensor of the high-osmolarity glycerol (HOG) 
response pathway (Lu et al. 2003).  These results suggest that MOG1 can interact with a 
plasma membrane protein.  Thus, our finding of the interaction between MOG1 and 
membrane protein Nav1.5 is no surprise.  Oki and co-workers recently showed that yeast 
MOG1 can also interact with Cid13 (a poly(A) polymerase for suc22 mRNA encoding a 
subunit of ribonucleotide reductase) with a potential role in regulation of cell cycle S-M 
transition (Oki et al. 2007).  In addition, genetic suppression studies in yeast implicated 
that MOG1 could be required for membrane localization of Opi3p, a phospholipid 
methyltransferase required for membrane formation, and might play a role in Ssp1-
mediated stress response pathway (Oki et al. 2007).  To date, all studies that explored the 
roles of MOG1 were either in vitro studies or involved yeast.  The results from the 
present study, for the first time, reveal a novel physiological role for MOG1 in 
mammalian cells in vivo and suggest that this small protein is a critical component in the 
multi-protein Nav1.5 complex with a modulator role in determining the amplitude of 
cardiac sodium currents.  The function(s) of mammalian MOG1 may not overlap 
completely with yeast MOG1 as human MOG1 failed to fully replace the yeast MOG1 in 
a complementation test of growth defects of a MOG1 deletion yeast strain (Marfatia et al. 
2001).    
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We found that in cardiomyocytes, MOG1 was mostly localized on cell membrane 
and outside of the nucleus (Fig. 2.8E).  In HEK293 cells, it was reported that MOG1 was 
expressed throughout the cell, including the nucleus and cytoplasm (Marfatia et al. 2001), 
however, the study could not distinguish whether MOG1 was also localized on plasma 
membrane due to complication of strong signal of MOG1 in cytoplasm.  The cell-specific 
subcellular localization of MOG1 in cardiomyocytes vs. HEK293 cells is an interesting 
observation, but the molecular mechanism warrants further investigations.  Cell- or 
tissue-specific proteins that interact with MOG1 may be a rational explanation for the 
observation.  The interaction with Nav1.5 or other cardiac specific membrane proteins is 
expected to recruit MOG1 to the plasma membrane. 
In summary, we identified MOG1 as a new interacting protein for Nav1.5.  We 
further demonstrated that MOG1 modulated the gating kinetics of Nav1.5 and was 
required for the function of Nav1.5 channels.  This study may have implications in 
understanding of the normal physiology of the heart as well as the disease mechanism for 
long QT syndrome, Brugada syndrome, cardiac conduction disease, and other diseases 
linked to the cardiac sodium channel Nav1.5.  Future studies will likely offer more 
insights into its role and relevance in myocardial functions. 
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CHAPTER III 
 
 
IDENTIFICATION OF GENES DIFFERENTIALLY EXPRESSED IN 
TRANSGENIC MICE WITH CARDIAC EXPRESSION OF LQTS MUTATION   
N1325S OF SCN5A BY EXPRESSION PROFILING: INDUCTION OF HIGH 
STAT1 EXPRESSION IN TRANSGENIC MICE WITH LQTS AND HEART 
FAILURE1
 
 
3.1.  ABSTRACT
Cardiac-specific expression of the N1325S mutation of SCN5A in transgenic 
mouse hearts (TG-NS) resulted in long QT syndrome (LQTS), ventricular arrhythmias 
(VT), and heart failure.  In this study we carried out oligonucleotide microarray analysis 
to identify genes that are differentially expressed in the TG-NS mouse hearts.  We 
identified 33 genes in five different functional groups that showed differential expression.  
None of the 33 genes are ion channel genes.  STAT1, which encodes a transcription factor 
involved in apoptosis and interferon response, showed the most significant difference of 
1Most of the data in this chapter have been published as Wu L et al. (2007) Biochem Biophys Res Commun 
358:449-454.  However this chapter has been rewritten for the purpose of this dissertation. 
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expression between TG-NS and control mice (a nearly 10-fold increase in expression, P = 
4×10−6).  The results were further confirmed by quantitative real-time PCR and Western 
blot analyses.  Accordingly, many interferon response genes also showed differential 
expression in TG-NS hearts.  This study represents the first microarray analysis for LQTS 
and implicates STAT1 in the pathogenesis and progression of LQTS and heart failure. 
  
3.2.  INTRODUCTION 
       The long QT syndrome (LQTS) is characterized by prolongation of the QT 
interval and T wave abnormalities on electrocardiograms (ECG) (Curran et al. 1995 and 
Wang et al. 1995).  LQTS is associated with symptoms including syncope, seizures and 
sudden death caused by a specific ventricular arrhythmia, torsade de pointes (Curran et al. 
1995 and Wang et al. 1995).  One of the major genes identified for LQTS is the SCN5A 
gene on chromosome 3p21–23 (LQT3), which accounts for 10–20% LQTS cases (Wang 
et al. 1995).  SCN5A encodes a voltage-gated sodium channel Nav1.5, which is mainly 
expressed in the heart and responsible for the generation and rapid propagation of 
electrical signals (action potentials) in cardiomyocytes (Gellens et al. 1992).  Besides 
gain-of-function mutations associated with LQTS, loss of function mutations in SCN5A 
were demonstrated to be involved in the pathogenesis of both Brugada syndrome (Chen 
et al. 1998) and progressive cardiac conduction defects (PCCD) (Tan et al. 2001).  
Mutations of SCN5A have also been reported to be involved in dilated 
cardiomyopathy/heart failure and atrial fibrillation (Olson et al. 2005 and Zicha et al. 
2004). 
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      The N1325S mutation in SCN5A is a substitution of an asparagine residue by a 
serine residue at position 1325 in the intracellular region of domain III S4–S5 of Nav1.5, 
and is one of the earliest mutations identified in LQT3 families (Wang et al. 1995).  It 
disrupts the Na+ channel inactivation and generates the late persistent inward current INa.  
Overexpression of the N1325S mutation in Xenopus oocytes and HEK293 cells induced 
dispersed reopening in the late inactivation phase, which produced a late persistent 
inward sodium current (Dumaine et al. 1996 and Wang et al. 1996).  We have expressed 
the SCN5A N1325S mutation in the mouse heart (TG-NS mice) (Tian et al. 2004).  The 
TG-NS transgenic mice showed prolongation of the QT interval on ECG and high 
incidences of spontaneous polymorphic VT followed by sudden cardiac death (Tian et al. 
2004 and Tian et al. 2007).  The electrophysiological studies of cardiomyocytes from the 
transgenic mice showed that the N1325S mutation produced a late sodium current and 
prolonged the cardiac action potential duration, which is expected to prolong the QT 
interval on ECG (Tian et al. 2004 and Yong et al. 2007).  Recent studies also detected the 
phenotype of dilated cardiomyopathy and heart failure in TG-NS mice (Zhang et al. 2006) 
as well as in a human patient with the N1325S mutation of SCN5A (Yong et al. 2007).  
Age-dependent apoptosis and abnormal calcium handling were also demonstrated in the 
TG-NS cardiomyocytes, and are the likely causes of dilated cardiomyopathy and heart 
failure (Zhang et al. 2007).  However, the molecular mechanism for cardiomyocyte 
apoptosis in TG-NS mice is not known.  In this study we found that the expression of the 
STAT1 gene was highly induced in TG-NS hearts, which may be a cause or mediator of 
apoptosis in these mice.  
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  STAT1 is a member of the Signal Transducers and Activators of Transcription 
family of transcription factors which mediate various biological responses, including cell 
proliferation, differentiation, survival and apoptosis.  The signals are transduced from 
various ligands (cytokines, growth factors, stress-induced stimuli) to the nucleus through 
Janus tyrosine kinases (JAKs) or mitogen-activated protein (MAP) kinases (Adamkova et 
al. 2007).  Seven different STAT family members have been identified, which are 
activated by different cytokines (Stephanou et al. 2003).  STAT1 has two alternative 
RNA splicing isoforms, STAT1α (p91) and STAT1β (p84) (Schindler C et al. 1992).  
STAT1β lacks 38 amino acids at the C terminus.  STAT1 forms homodimers or 
heterodimers with STAT3, which binds to the interferon-gamma activated sequence 
(GAS) on promoters and activates the expression of interferon stimulated genes (ISG).  
Upon stimulation by IFN-α or IFN-β, STAT1 forms a heterodimer with STAT2 and binds 
to the interferon stimulated response element  (ISRE) on promoters (Katze et al. 2002).  
STAT1 has been shown to be involved in apoptosis during myocardial ischaemia and 
oncogenesis (Stephanou et al. 2000, Adamkova et al. 2007).  STAT1 mediates the 
response to interferon (IFN)-α and IFN-γ and has been shown to be pro-apoptotic 
(Stephanou et al. 2003).  STAT1-deficient mice are more susceptible to development of 
tumors, which implicates STAT1 in oncogenesis (Adamkova et al. 2007).  No transgenic 
mice with over-expression of STAT1 were developed, thus, the physiological effect for 
over-expression of STAT1 is unknown.  
      Microarray analysis is an unbiased approach to study expression of thousands of 
genes simultaneously in a system.  To date, no microarray analysis or other large-scale 
gene expression studies have been performed for LQTS, either in humans or mice. Here, 
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we took advantage of our mouse model for LQTS, the TG-NS mice, to explore global 
gene expression re-programming in these mice.  We used mouse oligonucleotide 
microarrays with 22,690 unique genes to determine gene expression differences between 
TG-NS and non-transgenic control mice.  A surprisingly large number of genes showed 
differential expression between the two types of mice, which may be partly caused by the 
marked up-regulation of transcription factor STAT1, as validated by RT-PCR and 
Western blot analyses.  These results implicate STAT1 in the pathogenesis and 
progression of LQTS and heart failure in this model and may offer insights into the 
observation of cardiomyocyte apoptosis in TG-NS mice.  
 
3.3.  MATERIALS AND METHODS  
Transgenic mice 
Human mutant SCN5A gene with the LQTS-causing mutation N1325S was 
expressed in the mouse heart using a cardiac specific promoter, the mouse α-myosin 
heavy chain (α-mMHC) promoter, and we named this line of transgenic mice as TG-NS.  
Transgenic mice with cardiac-specific expression of wild type SCN5A, TG-WT, were 
also created.  The creation of TG-NS and TG-WT mice was reported by us previously 
(Tian et al. 2004 and Zhang et al. 2007), and they carry the comparable number of the 
transgenes and have a comparable level of SCN5A expression.  Genotyping of the 
positive TG-NS mice was performed by polymerase chain reactions (PCR) using 
genomic DNA isolated from mouse tails/toes using the tail lysis buffer (50 mM Tris–HCl, 
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100 mM EDTA, 100 mM NaCl, 1% SDS).  We used PCR primers 5′-TGT CCG GCG 
CTG TCC CTG CTG-3′ and 5′-CTC ATG CCC TCA AAT CGT GAC AGA-3′ for 
specific amplification of the SCN5A transgene and primers 5′-GGC ACC TGC TGC 
AAC GCT CTT T-3′ and 5′-GGT GGG CAC TGG AGT GGC AAC TT-3′ for 
amplification of AGGF1 that serves as an internal control for quality of mouse genomic 
DNA.  PCR was performed using standard procedures.  
Microarray analysis 
Total RNA was prepared from heart tissues of the non-transgenic control and TG-
NS mice.  First, heart tissues were homogenized by a polytron homogenizer (PT3100, 
Dispersing and Mixing Technology by Kinematica).  Total RNA was then isolated using 
the TRIzol reagent (Invitrogen).  The integrity and purity of the RNA was confirmed 
visually on a 1% denaturing agarose gel, and by measuring the optical density ratio 
(A260/A280).  Double-stranded complementary DNA (ds-cDNA) was synthesized from 
15 µg of total RNA using the Superscript Choice System (Invitrogen) with an HPLC-
purified oligo-dT primer containing a T7 RNA polymerase promoter (GENSET, La Jolla, 
CA) as instructed by the manufacturer.  The cDNA was extracted by the Phase Lock Gel 
(PLG) kit (Eppendorf) and purified by ethanol precipitation.  In vitro transcription was 
performed with 1 µg of ds-cDNA using the ENZO BioArray RNA Transcript Labeling 
kit (ENZO Diagnostics).  Fragmentation of biotinylated cRNA (20 µg), hybridization, 
washing, and staining were performed following the instructions by Affymetrix by the 
CWRU Gene Expression Core Facility.  The Mouse Genome MOE430A arrays 
(Affymetrix) were used.  Each array contains about 22,690 genes.  
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Statistical analysis  
Microarray data was extracted from scanned images.  GeneSpring 7.0 
(Silicogenetics) was used to compare the data from three transgenic mice (6–8 months of 
age, male) with those from three non-transgenic control littermates.  All samples were 
considered as one group of replicates.  The algorithm to generate a list of genes that 
showed a statistically significant difference between the two groups was described 
previously (Archacki et al. 2003 and Tan FL et al. 2002).  The median value for group 
comparisons was used.  All raw data with a score less than zero were set to zero.  Genes 
were further filtered by an absolute call: present (P) or marginally present (M) in the two 
groups for the up-regulated genes and down-regulated genes.  
Quantitative real-time PCR (RT-PCR) 
Quantitative RT-PCR was performed using an ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems).  Total RNA was extracted from hearts using 
TRIzol (Invitrogen).  Reverse transcription was performed with 5 µg of RNA using the 
Superscript Choice System (Invitrogen).  Primers spanning exon-intron junctions were 
designed to avoid amplification of genomic DNA.  PCR conditions were 50°C for 2 min 
and 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.  
Fluorescence changes were monitored with SYBR Green PCR Supermix (VWR) after 
every cycle, and melting curve analysis was performed at the end of 40 cycles to verify 
PCR product (0.5°C/s increase from 55–99°C with continuous fluorescence reading). The 
18S gene was used to normalize samples for comparison.  To quantify changes in gene 
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expression, the ∆∆Ct method was used to calculate the relative fold changes as previously 
described (Livak et al. 2001).  
Western blot analysis 
To determine the expression level of the STAT1 protein, total proteins were 
extracted from hearts of transgenic and normal mice.  Hearts from 7-8 months old mice 
were homogenized with Polytron, and lysed on ice with the lysis buffer (0.5% NP-40, 20 
mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA and proteinase inhibitor cocktail).  
The protein concentration was measured using the Bradford method (Bio-Rad).  Western 
blot analysis was then performed.  Briefly, equal amounts of protein extracts were 
separated on 10% SDS–polyacrylamide gels by electrophoresis.  The blots were 
incubated with agitation at room temperature in the presence of a rabbit polyclonal anti–
STAT1 antibody (Santa Cruz Biotechnology) (diluted in 1:500 in 0.3% BSA in PBST).  
The signal was detected using enhanced chemiluminescence (ECL kit, Amersham 
Biosciences).  An anti-β-actin antibody and an anti-GAPDH antibody (Sigma–Aldrich) 
were used as loading controls at 1:1,000 dilution in PBST.  
 
3.4.  RESULTS 
Identification of genes differentially expressed in the hearts from TG-NS mice  
We investigated the gene expression profiles from three TG-NS mice and three 
age- and sex-matched control mice using the Affymetrix Mouse Genome MOE430A 
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Arrays.  2492 of 22,690 genes showed significant expression differences between the two 
groups if P 0.05 (Welch t-test).  Because of the large number of genes identified, filters 
exceeding 2- and 5-fold changes and several different P values were applied.  The results 
are summarized in Table 3.1. With P 10−5, only two genes, STAT1 encoding signal 
transduction and activator of transcription factor 1 and DLM-1 encoding Z-DNA binding 
protein 1, showed an expression difference between two groups of mice.  At P value of 
10−4, 11 genes showed differential expression of 5-fold, 9 up-regulated and 2 down-
regulated (9↑, 2↓).  At P value of 10−3, 33 genes (31↑, 2↓) showed expression differences 
of 5-fold.  The number of genes increased to 14 at P 10−4 and 65 at P 10−3 if the cut 
off expression difference was set to 2-fold (Table 3.1).  
  Our further analysis was focused on genes showing a large differential expression 
difference, i.e. those showing 5-fold expression differences and P value of 0.001.  As a 
result, 31 genes were found to be up-regulated and 2 genes down-regulated in TG-NS 
mice (Table 3.1).  These genes can be divided into five functional groups: 11 genes are 
involved in interferon-responses; 4 genes are related to apoptosis and inflammation; 4 
genes may mediate other immune responses; 4 genes encode enzymes; 11 unknown 
genes (Table 3.2 and Supplementary Table 3.1).  
Validation of microarray results by real-time PCR (RT-PCR)  
      To verify the results from the microarray analysis, quantitative RT-PCR was 
performed with 9 additional TG-NS and 7 control mice (6–8 months of age).  Results 
from RT-PCR analysis of 6 highly significant genes, including STAT1, Usp18, Oas1 1G, 
Helicard, Trim34 delta, and Phgdh, are shown in Table 3.3.  The real-time PCR results  
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Table 3.1. Summary data for the number of genes showing differential expression in 
TG-NS hearts    
 
 
Fold difference of 
expression 
                                                 P value 
 0.01 0.001 0.0001 0.00001 
Up-regulated genes     
2-fold 470 54 12 2 
5-fold 101 31 9 2 
Down-regulated genes     
2-fold 306 11 2 0 
5-fold 53 2 2 0 
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Table 3.2 List of genes showing differential expression in TG-NS hearts by 
microarray analysis1   
 
 
Accession # Symbol Gene   P value Fold of 
change 
(A)  Genes involved in interferon (IFN)-signaling pathways 
 
NM_008332.1 Ifit 2 Interferon-induced protein with 
tetratricopeptide repeats 2 
1.3 x 10-4 43.9 
NM_011909.1 Usp18 Ubiquitin specific protease 18 6.5 x 10-5 31.8 
NM_010501.1 Ifit 3 Interferon-induced protein with 
tetratricopeptide repeats 3 
8.3 x 10-4 31.5 
NM_008331.1 Ifit 1 Interferon-induced protein with 
tetratricopeptide repeats 1 
2.2 x 10-4 26.0 
NM_016850.1 Irf 7 Interferon regulatory factor 7 1.3 x 10-4 18.6 
NM_018734.1 Gbp3 Guanylate nucleotide binding protein 
3 
1.8 x 10-4 13.5 
AF136520  Dlm-1 Tumor stroma and activated 
macrophage protein DLM-1 
8.6 x 10-6 12.9 
NM_009283 STAT1 
2
Signal transducer and activator of 
transcription 1      
4.0 x 10-6 9.8 
AB067533.1 Oasl 9 2,5-Oligoadenylate synthetase-like 9 9.8 x 10-4 6.6 
BC018470 Oasl 
1G 
2'-5' Oligoadenylate synthetase 1G 2.0 x 10-4 6.5 
AY090098.1 Isg 12 Interferon stimulated gene 12 2.7 x 10-4 6.2 
     
NM_009283 STAT1 
2
Signal transducer and activator of 
transcription 1      
4.0 x 10-6 9.8 
AY075132 Helicar
d 
Helicard 2.1 x 10-5 7.9 
AF220142 Trim34 
delta 
Tripartite motif protein  34 delta 8.1 x 10-5 5.5 
NM_126166 Tlr3 Toll-like receptor 3 2.5 x 10-4 5.4 
 
(B)  Genes with a potential role in apoptosis and inflammation  
 
AY075132 Helicar
d 
Helicard 2.1 x 10-5 7.9 
AF220142 Trim34 
delta 
Tripartite motif protein  34 delta 8.1 x 10-5 5.5 
NM_126166 Tlr3 Toll-like receptor 3 2.5 x 10-4 5.4 
1Additional genes showing differential expression in TG-NS hearts are listed in Appendix 
C. 2STAT1 is involved in both IFN signaling and apoptosis. 
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Table 3.3  Conformation of results from mircroarray analysis by RT-PCR    
 
 
Gene Microarray1 RT-PCR2
STAT1:Signal transducer and activator of transcription 1 9.8 8.4 
Usp18:  Ubiquitin specific protease 18 31.8 65.9 
Oas1 1G:  2'-5' Oligoadenylate synthetase 1G 6.5 14.9 
Helicard:  Helicard 7.9 3.4 
Trim34 delta:  Tripartite motif protein Trim34 delta 5.5 7.9 
Phgdh:  3-Phosphoglycerate dehydrogenase 53.8 66.3 
1data of fold difference of expression between 3 TG-NS and 3 control mice.  2data of fold 
difference of expression between 9 TG-NS and 7 control mice; no overlapping of 
samples between the microarray and RT-PCR studies. 
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generally confirmed the results from microarray analysis.  Liner regression analysis 
demonstrated a strong positive correlation between the two technological platforms with 
R=0.93.  
STAT1 showed the most significant differential expression in TG-NS mice  
          STAT1 is the gene showing the most significant expression difference between TG-
NS and control mice with a P value of 4.0 × 10−6 and a fold difference of 9.8 (Table 3.2).  
In addition to the RT-PCR analysis described above (Fig. 3.1A and Table 3.3), Western 
blot analysis was also used to validate the finding of increased STAT1 expression in TG-
NS mice compared to control littermate mice (Fig. 3.1B).  Western blot analysis 
demonstrated that the basal expression level of the STAT1 protein in non-transgenic 
control mice was low, however, it dramatically increased in TG-NS hearts (Fig. 3.1B).   
Recently, we created and studied transgenic mice with cardiac-specific expression 
of wild type SCN5A (TG-WT) (in contrast to TG-NS with mutant SCN5A containing the 
N1325S mutation) (Zhang T et al. 2007).  TG-WT mice did not develop LQTS, VT, or 
heart failure  (Zhang T et al. 2007), thus they could serve as an excellent control for TG-
NS mice (note that the TG-WT mice were not available when the microarray project 
started).  Western blot analysis was used to compare the expression level of the STAT1 
protein between TG-NS to TG-WT mice.  As shown in Fig. 3.1C, the expression level of 
STAT1 in TG-WT heart was comparable to that in non-transgenic control hearts, but 
much lower than that in TG-NS hearts.  These results suggest that induction of STAT1 
expression is specific to TG-NS mice with the SCN5A mutation N1325S.  
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Fig. 3.1. Markedly increased expression of STAT1 in TG-NS hearts. (A) Quantitative 
RT-PCR analysis with RNA isolated from 9 TG-NS and 7 NTG (non transgenic control) 
hearts (age = 6–8 months). Data were normalized to 18S RNA expression in the same 
samples and reported as fold changes (mean ± SE) from levels in control mice 
(*P = 0.0016). (B) Western blot analysis of STAT1 from three NTG and three TG-NS 
hearts (age = 6–8 months). β-Actin was used as loading control. The experiment was 
repeated three times and similar results were obtained. (C) Western blot analysis of 
STAT1 from non-transgenic control (NTG), TG-NS, and TG-WT hearts (age = 6–8 
months). The experiment was repeated twice and similar results were obtained. Note that 
TG-NS and TG-WT have the comparable copy number of the transgene and a similar 
level of expression of the cardiac sodium channel (see Reference by Zhang T et al. 2007). 
The only difference between these two types of mice is that TG-NS mice carry the 
mutant N1325S SCN5A and TG-WT mice carry the wild type SCN5A.    
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3.5.  DISCUSSION 
Microarray analysis is a large scale study that can provide unbiased assessment of 
expression of thousands of genes in a cell or tissue simultaneously.  To date, no 
microarray analysis has been reported for LQTS either in the humans or mice.  We 
performed a microarray study using a mouse model for LQTS, the TG-NS mice with 
cardiac expression of the SCN5A mutation N1325S associated with LQTS.  Microarray 
analysis revealed 33 genes showing marked differential expression between TG-NS and 
wild type mice (>5-fold difference, P 0.001).  The results from microarray analysis 
were almost identical to that from the follow-up RT-PCR analysis using independent 
samples for all selected genes.  Our results suggest the involvement of expression 
remodeling in the progression of LQTS.  Furthermore, the results from this study suggest 
that in addition to its effects on basic biophysical properties of the cardiac sodium 
channel, the N1325S mutation has a more profound effect on cardiomyocytes in vivo.  
The gene that showed the most significant difference between TG-NS and wild 
type mice is STAT1.  Follow-up RT-PCR and Western blot analysis confirmed that 
expression of STAT1 was markedly increased in TG-NS myocytes compared to non-
transgenic control cells.  Further analysis showed that STAT1 protein expression was 
also much higher in TG-NS hearts than in TG-WT hearts with cardiac expression of wild 
type SCN5A (Fig. 3.1C).  STAT1 is a key signaling protein that functions as a transducer 
of cytokine signaling and as a sensor responding to cellular stresses, in particular, IFN 
response (Stephanou et al. 2003).  Thus, it was interesting to note that many genes 
involved in the IFN response also showed increased expression in TG-NS myocytes, for 
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example, Usp18, Ifit1, Ifit2, Ifit3, Irf7, Gbp3, Dlm-1, Oasl 9, Oasl 1G, and Isg 12 that all 
showed many fold increases of expression (Table 3.2).  The molecular mechanism for 
induction of high STAT1 expression in TG-NS hearts is not clear, however, abnormal 
handling of intracellular calcium transients detected in TG-NS cardiomyocytes (Yong SL 
et al. 2007) may be a likely cause.  
STAT-1 has been shown to induce apoptosis.  Human fibroblast cells deficient in 
STAT1 were resistant to TNF-α-induced apoptosis (Kumar et al.1997).  Neonatal rat 
cardiomyocytes subjected to ischemia for 4 h showed increased expression of STAT1, and 
cardiomyocytes transfected with STAT1 showed increased apoptosis with exposure to 
ischemia (Stephanou et al. 2000).  A trend of increased apoptosis in the absence of 
exposure to ischemia was also detected in cardiomyocytes transfected with a STAT1 
construct compared to control cells transfected with the vector (Fig. 3A in Stephanou et 
al. 2000).  Because age-dependent apoptosis has been detected in TG-NS mouse hearts 
(Zhang T et al. 2006), we speculate that increased expression of STAT1 may be a cause 
for apoptosis in these mice.   
In summary, our microarray analysis of a transgenic mouse model for LQTS, TG-
NS, demonstrated that gene expression remodeling existed in these mice.  Of a particular 
interest was the finding of highly increased STAT1 expression, which may provide 
insights into the findings of cardiomyocyte apoptosis in TG-NS mice and high risk of 
heart failure in these mice.  
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CHAPTER IV 
 
INVESTIGATION OF LOCALIZATION OF NAV1.5 IN NON-CARDIAC 
TISSUES:  EVIDENCE OF Nav1.5 IN THE MOUSE BRAIN1
 
4.1   ABSTRACT 
 
SCN5A encodes a sodium channel α-subunit Nav1.5 that is predominantly 
expressed in the heart.  Mutations in the human Nav1.5 gene cause long QT syndrome 
and Brugada syndrome that are characterized by cardiac arrhythmias and sudden death 
during sleep or at rest.  SCN5A mRNA was recently shown to be present in the rat and 
human brain.  In this report, we determined the distribution of Nav1.5 protein in the 
mouse brain.  We generated a polyclonal antibody specific to Nav1.5.  The anti- Nav1.5 
antibody was used for immunohistochemical analysis of the Nav1.5 distribution.  We 
found that Nav1.5 protein was present widely throughout the brain, and was found in the 
cerebral cortex, limbic system, basal ganglion, thalamus, hypothalamus, cerebellum, and 
brainstem.  The distribution of Nav1.5 immunoreactivity appeared to be more widespread  
1Most of the data in this chapter have been published as Wu l et al. (2002) Neuroreport 13:2547-2551.  
However this chapter has been rewritten for the purpose of this dissertation. 
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than previously reported for the mRNA.  Notably, Nav1.5 protein was clustered at a high 
density in neuronal processes and nerve fiber bundles, but not in cell bodies.  Further 
confocal microscopic analysis revealed that Nav1.5 protein was localized on the surface 
membrane of the neuronal processes in the brain, and surrounded the neurofilaments.  
The wide distribution of Nav1.5 protein in the brain and its distinct localization to the 
membrane of neuronal processes suggest that this protein may play a role in the 
physiology of the central nervous system.  Abnormal neuronal activity associated with 
Nav1.5 mutations might affect the coordination of cardiac rhythm by an indirect 
mechanism, which may trigger seizures, syncope, life-threatening arrhythmias, or sudden 
death in arrhythmic and epileptic patients.   
 
4.2.   INTRODUCTION 
Voltage-dependent sodium channels are transmembrane proteins that are 
responsible for generating action potentials and for rapid conduction of electrical signals 
in excitable cells (Catterall et al. 2000).  Sodium channels are classified into three types 
based on their sensitivity to blockade by tetrodotoxin (TTX): TTX-sensitive Na channels 
(TTXs), TTX-resistant Na channels (TTXr), and TTX-insensitive Na channels (TTXi) 
(Donahue et al. 2000, Fozzard et al. 1996).  In the brain, six TTXs Na channels have been 
identified, including Nav1.1, Nav1.2, Nav1.3, Nav1.6, Nav1.7.  Only one TTXr channel, 
Nav1.9, has been identified in the brain (Jeong et al. 2000).  Recent studies suggested that 
SCN5A may be another gene that is responsible for generating TTXr Na currents in the 
brain (Donahue et al. 2000; Hartmann et al. 1999).  TTXr Na channels generate currents 
that are slower, but recover from inactivation much faster than TTXs channels (Elliott et 
 86
al. 1993), suggesting a possible role of TTXr sodium channels in sustained firing of 
neurons or as pace-makers.  In this study, we investigated the localization pattern of 
another TTXr sodium channel, Nav1.5, in the mouse brain using immunohistochemistry. 
SCN5A encodes the cardiac sodium channel with 2,016 amino acids and a 
calculated molecular weight of 227 kDa (Gellens et al. 1992).  The putative structure of 
Nav1.5 consists of four homologous domains (I-IV), each containing six transmembrane 
segments (S1-S6).  Nav1.5 mutations cause syncope, seizures, and sudden death triggered 
by lethal cardiac arrhythmias associated with long QT syndrome (LQTS), idiopathic 
ventricular fibrillation including Brugada syndrome and cardiac conduction disease 
(Wang et al. 1995a; Chen et al. 1998).  Nav1.5 was originally identified as a cardiac 
sodium channel.  Subsequently, it was shown to be expressed in the brain at the mRNA 
level (Donahue et al. 2000; Hartmann et al. 1999).  In situ hybridization, reverse 
transcription polymerase chain reaction (RT-PCR), and RNase protection assays detected 
the presence of transcripts of SCN5A in the human and rat brain tissues.  Restricted 
regional expression of SCN5A mRNA involved piriform cortex and subcortical limbic 
nuclei (Donahue et al. 2000; Hartmann et al. 1999), and these two regions are related to 
epilepsy.  These findings may explain why Nav1.5 mutations are associated with seizures.  
However, the distribution of Nav1.5 in the brain at the protein level has not been 
investigated previously.  Here, we demonstrate selective expression of Nav1.5 at the 
protein level in regions of the mouse central nervous system.   
In this study, we investigated the localization pattern of Nav1.5 protein in the 
mouse brain tissues using immunohistochemistry.  We generated an antibody directed 
against a unique peptide region at the N-terminus of Nav1.5.  The antibody was used to 
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define the distribution of Nav1.5 in mouse brain.  We demonstrated that Nav1.5 protein 
was widely localized in the cerebral cortex, thalamus, hypothalamus, basal ganglia, 
cerebellum and brainstem.  Our studies confirmed the distribution of Nav1.5 protein in 
some regions that were previously shown to contain the corresponding mRNA, but also 
revealed the presence of Nav1.5 protein in new brain regions where Nav1.5 gene 
expression has not been previously reported.  Our data also indicate that Nav1.5 protein is 
expressed and localized on the plasma membrane of the neuronal processes, but not in the 
cell bodies.  The regional distribution of Nav1.5 in the brain suggests that Nav1.5 might 
regulate neuron excitability.      
     
4.3   MATERIALS AND METHODS  
Materials  
An Nav1.5-specific polyclonal antibody was developed against a synthetic 
polypeptide (AC-RPQLDLQASKKLPDLYC-Amide) corresponding to a unique portion 
of the N-terminus of the cardiac sodium channel Nav1.5.  The antibody was generated 
and purified as described (Harlow et al. 1988).   
            The mouse anti-neurofilament 200 antibody (clone NE14) was purchased from 
Sigma (St Louis, MO) and used at 1:40 dilution for immunohistochemistry.  Fluorescein-
conjugated secondary antibodies were from Jackson Immuno Research Laboratories 
(West Grove, PA), and used at 1:200 dilution.  The Vectastain elite ABC kit, DAB 
substrate kit, and Vectashield anti-fading mounting media were from Vector Laboratories 
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(Burlingame, CA).  The brain tissues for Western blotting and immunohistochemical 
analyses were from the mouse strain c57BL.  
 
Western blot analysis 
       Mouse tissues from the heart, brain, kidney, liver, and skeletal muscle were 
homogenized with a glass tissue grinder (Wheaton, Millville, NJ) in 1X PBS buffer 
containing 0.1% NP-40, 0.05% sodium deoxycholate, and a protease inhibitor cocktail 
mix (Roche Biochemicals, Germany).  The sample was centrifuged at 3,000 rpm for 10 
minutes, and the supernatant was transferred to a microcentrifuge tube.  The supernatant 
was then undergone ultracentrifugation at 40,000 rpm for 30 minutes.  The pellet 
containing the membrane fraction of proteins was resuspended in the loading buffer 
containing 2% SDS, and denatured at room temperature for 30 minutes before loading 
onto SDS-PAGE.  Western blot analysis was performed as described (Harlow et. al. 1988) 
with the anti- Nav1.5 antiserum as the primary antibody.  The secondary antibody was 
horseradish peroxidase-conjugated donkey anti-rabbit IgG (NA 934, Amersham 
Pharmacia Biotech, Inc., Piscataway, NJ).  ECL Western blotting detection reagents 
(Amersham Pharmacia Biotech, Inc., Piscataway, NJ) were used to visualize the protein 
signals. 
For HEK293 cells with or without expression of Nav1.5, cells were lysed in the 
lysis buffer (1% Triton-100, 150 mM NaCl, 50 mM Tris-HCl, pH7.5, 1 mM EDTA) with 
a protease inhibitor cocktail mix on ice for 30 min.  The sample was then centrifuged at 
14,000 rpm for 25 min at 40C.  The supernatant was used for Western blot analysis as 
described above.   
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Immunohistochemistry  
            Immunostaining was carried out as previously described (Nishiyama, et al. 1997) 
with minor modifications.  Briefly, mouse brain sections fixed with 4% 
paraformaldehyde and embedded with paraffin or frozen sections were pretreated with 
hydrogen peroxide, blocked in blocking buffer (5% bovine serum albumin and 0.3% 
Triton X-100 in 1x PBS) for 2 hr, and then incubated with the primary antibody (1:250 
dilution) at 4°C for 24 hours.  The sections were then incubated with the biotin-
conjugated secondary antibody and the avidin-biotin complex solution (Vectastain Elite 
ABC Kit).  Immunoreactive signal was developed using the DAB substrate kit (Vector 
Laboratories, Burlingame, CA).  
            In control experiments, serial brain sections were stained with the primary anti- 
Nav1.5 antibody preincubated with an excessive amount of the immunizing peptide 
antigen (100 µg of peptide vs. 13.7 µg of the anti- Nav1.5 antibody).  
Double immunofluorescence staining was carried out using the protocol similar to 
those reported previously (Nishiyama et al. 1999).  In brief, mouse brain sections of 12 
µm thickness were prepared from paraffin-embedded or frozen tissues, blocked, and 
incubated with the mixture of primary antibodies (the anti-Nav1.5 antibody and the 
monoclonal anti-neurofilament 200 antibody) at 4°C for 24 hours.  The sections were 
then incubated with a secondary antibody mixture containing the FITC-conjugated and 
Texas Red-conjugated secondary antibodies at room temperature for 2 hours.  The 
immunostained slides were mounted with anti-fading media, and visualized under a 
confocal microscope. 
 
 90
Confocal microscope and image processing 
Tissue sections immunostained with DAB were analyzed with transmitted light or 
Nomarski optics using a Zeiss Axiophot photomicroscope.  Images observed were 
digitized using a Hamamatsu CCD camera, and transferred to a Power Macintosh G4 
computer for digital image processing.  Digital images were processed using software 
Adobe PhotoShop 5.5. 
For immunocytochemical analysis, a confocal laser-scanning microscope (SP2; 
Leica, Heidelberg, Germany) equipped with 40x, 63x and 100x infinity-adjusted oil 
immersion objectives and double-channel photodetectors was used.  By precisely 
stepping the microscope stage in the vertical z-axis, a series of optically thin, perfectly 
focused images were collected at identical x-y planes through the specimen.  In general, 
each data set collected on the confocal microscope was processed with the 3D software of 
the Leica Scan Ware operating system, and used to construct an extended focus image, 
i.e., a computer-averaged assembly of some or all optical sections in the data set.  These 
procedures resulted in a perfectly focused image through the depth of the specimen which 
was then saved in a TIFF file format and transferred to a Power Macintosh G4 for image 
processing.  Digital images were colorized, and then combined and manipulated using 
Adobe PhotoShop 5.5.   
 
Over-expression of NaV1.5 in HEK293 and P19CL6 cells 
Wild type Nav1.5 cDNA was cloned into the pcDNA3 vector (Invitrogen, 
Carlsbad, CA) for expression in HEK293 and P19C16 cells (Wan et al. 2000; Wan et al. 
2001).  Approximately 1 x 105 P19CL6 cells were seeded on chamber coverglass (Nalge 
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Nunc International, Naperville, IL) a day prior to transfection.  Two microliters of 
Lipofectamine (Invitrogene, Carlsbad, CA) was diluted in 50 µl of the serum free 
medium, and mixed with one microgram of Nav1.5 expression plasmid DNA in 50 µl of 
the serum free medium.  After incubation at room temperature for 20 minutes, the DNA-
Lipofectamine complexes formed and were added into chamber slide wells.  The serum 
free medium was replaced with the growth medium after 4-6 hours.  After 48 hours of 
incubation, the cells were ready for immunostaining.  The cells were fixed with 4% 
paraformaldehyde, blocked in the blocking buffer (5% bovine serum albumin and 0.3% 
Triton X-100 in 1x PBS), and incubated with the primary anti-Nav1.5 antibody.  The 
secondary antibody used was FITC-conjugated anti-rabbit IgG.  The images were 
visualized with a confocal microscope as described above.   
 
4.4.  RESULTS 
 
Characterization of the anti- Nav1.5 polyclonal antibody  
A polyclonal antibody specific to the Nav1.5 channel was generated using a 
peptide immunogen located at the cytoplasmic N-terminus of Nav1.5 protein (amino 
acids 53 to 68: RPQLDLQASKKLPDLY).  To confirm the specificity of the anti- Nav1.5 
antibody, we performed Western blot analysis on the membrane fractions of protein 
extracts from a number of mouse organs, including heart, kidney, liver, brain, skeletal 
muscle, and human embryonic kidney cells (HEK293) expressing human Nav1.5.  The 
antibody detected a band approximately the expected size of 227 kDa (Wang et al. 1996) 
strongly in the heart, and very weakly in the brain, but not in the kidney, liver, and 
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skeletal muscle (Fig. 4.1A).  These data are consistent with the results from Northern blot 
analysis (Gellens et al. 1992).  The antibody also yielded the expected 227 kDa band in 
the lane loaded with protein extract from the transfected cells containing Nav1.5 (Fig. 
4.1B).  No equivalent band was detected in the control non-transfected cells (Fig. 4.1B).  
These data suggest that our antibody is specific for Nav1.5.   
To further establish the specificity of this antibody, we determined whether the 
antibody binds to the cell membrane where Nav1.5 is known to be localized.  
Immunofluorescence staining with HEK293 and P19C16 cells transfected with the 
Nav1.5 expression construct DNA detected Nav1.5-imunoreactivity only on the plasma 
membrane (Fig. 4.1C).  No localization was evident when the antibody was pre-absorbed 
with an excessive amount of the peptide to which the antibody was prepared (Fig. 4.1C).   
Together, these data suggest that our anti- Nav1.5 antibody specifically recognizes 
Nav1.5 protein and that the wild type Nav1.5 protein is localized to the plasma membrane 
when expressed in non-neuronal cultured cells.    
 
Regional distribution of Nav1.5 protein in the brain  
Immunohistochemistry using this anti-Nav1.5 antibody was performed to 
determine the distribution of Nav1.5 immunoreactivity in the normal mouse brain.  Unlike 
the Nav1.5 mRNA, which was reported to be expressed primarily in the limbic system 
(Donahue et al. 2000; Hartmann et al. 1999), the Nav1.5 protein seemed to be more 
broadly expressed in various brain regions with some unique features (Fig. 4.2).  In the 
immunohistochemistry experiments, a negative control was carried out on the adjacent 
brain sections with the anti-Nav1.5 antibody pre-absorbed with the antigen peptide.  
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Fig. 4.1. Characterization of the anti-Nav1.5 antibody. (a) Western blot analysis of 
mouse membrane proteins from the heart, kidney, liver, brain, and skeletal muscle tissues 
with the anti-Nav1.5 antibody.  The positions of molecular weight markers are indicated. 
(b) Western blot analysis with protein extracts from HEK293 cells expressing Nav1.5 
(transfected cell), and control cells that were not transfected with the Nav1.5 expression 
construct (non-transfected cell). (c) Cellular localization of wild type human SCN5A 
protein on plasma membrane (green signal).  HEK293 cells (left) and P19CL6 cells 
(middle) transfected with the human SCN5A expression construct were immunostained 
with the anti-SCN5A antibody. No detectable immunofluorescence staining was observed 
with the anti-SCN5A antibody pre-absorbed with the peptide antigen (right). Bar = 5 µm. 
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Elimination of Nav1.5 immunoreactivity in the negative control experiments (compare 
Figs. 4.2A and 4.2B), as expected, demonstrated that positive Nav1.5 staining or the 
Nav1.5 -immunoreactivity represented the specific binding of our antibody to the 
immunogenic peptide sequence of Nav1.5.   
           In the forebrain of the adult mouse, a weak, but significant, Nav1.5 
immunoreactivity was observed in the cerebral cortex (Fig. 4.2C).  Within this region, the 
neuronal processes originating from cerebral cortical neurons were positively stained for 
Nav1.5, whereas little or no immunoreactivity was detected in the neuronal cell bodies or 
glial components in this region (Fig. 4.2C).  In contrast, none of the neurons in the 
dentate gyrus and hippocampus were positively stained for Nav1.5, and even the neuronal 
processes showed little Nav1.5 immunoreactivity in this area (data not shown).  
Interestingly, in the forebrain slides we observed intense Nav1.5 signals in the olfactory 
tract (Fig. 4.2D), and weak staining in the olfactory tubercule (data not shown).  
In the limbic system, little or no immunoreactivity for Nav1.5 was detected in the 
cell bodies in the septal nuclei, the diagonal band of Broca, the piriform cortex, and the 
amygdala, where Nav1.5 mRNA was reported to be expressed strongly (Donahue et al. 
2000; Hartmann et al. 1999).  However, moderate Nav1.5 signals were detected in the 
nerve fibers within this region (Fig. 4.2A).  The discrepancy between Nav1.5 mRNA 
localization and Nav1.5 protein distribution may be explained by our hypothesis that 
Nav1.5 protein is transported to the nerve fibers after synthesis in the cell bodies of 
neurons in the limbic system.  
In the basal ganglion, the anti- Nav1.5 antibody showed strong positive staining in 
the nerve bundles, also known as the pencil fibers, whereas the cell bodies in the striatal   
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Fig. 4.2.  Regional distribution of Nav1.5 protein in the mouse brain. (a) Some nerve 
fibers in the limbic system express Nav1.5 protein, whereas neuronal and glial cell bodies 
were not stained by the anti-Nav1.5 antibody. (b) An adjacent section to the section used 
in (a) was stained with the anti-Nav1.5 antibody pre-absorbed with the immunogenic 
peptide. (c) In the cerebral cortex, the neuronal processes, mainly axons, were positive 
for Nav1.5 protein, but little or no signal was observed in the cell bodies. (d) The 
olfactory tract had strong Nav1.5 signal. (e) In the striatum, Nav1.5 protein was mainly 
localized to the nerve fibers (the pencil fibers). (f) The cerebral peduncle was stained by 
the anti- Nav1.5 antibody. (g) In the brain stem, some nerve fibers in the lateral medulla 
were moderately positive for Nav1.5. (h) In the cerebellum, the white matter consisting of 
nerve fibers was strongly stained for Nav1.5, but there was no signal in the granular layer 
and the Purkinje cell layer. Bars = 100 µm. 
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nuclei showed little or no signal (Figs. 4.2E, 4.3A-4.3C).  Interestingly, Nav1.5-
immunoreactivity in the pencil fibers was significantly stronger within the caudate 
putamen (Fig. 4.2E, right half) than within the globus pallidus (Fig. 4.2E, left half).  It is 
important to note that not all the nerve tracts or nerve bundles through the mouse brain 
were positively stained for Nav1.5 immunoreactivity, for example, a huge nerve tract 
connecting both hemispheres in the corpus callosum was not positively stained for Nav1.5 
(data not shown).  These data suggest that the distribution of Nav1.5 protein is restricted 
to specific nerve tracts.   
In the diencephalon of the adult mouse brain, Nav1.5 immunoreactivity was also 
localized to the nerve fiber tracts, and little or no Nav1.5 signal was present in the cell 
bodies in the cerebral cortex.  The cerebral peduncle was intensively stained for Nav1.5 
(Fig. 4.2F).  A low level of Nav1.5 immunoreactivity was localized to the hypothalamic 
and thalamic nuclei, but the nerve fibers in the hypothalamic and thalamic regions 
showed more intense Nav1.5 signal than the cell bodies (data not shown).   
In the brainstem, intense Nav1.5 immunoreacitivy was localized to some spotty 
regions in the lateral medulla (Fig. 4.2G).  These signals seemed to correspond to discrete 
nerve tracts in the medulla.  Based on a report showing that Nav1.5 mRNA expression is 
located in the lateral paragigantocellular nuclei (LPGi) (Donahue et al. 2000), some of 
the nerve tracts with Nav1.5 immunoreactivity shown in this study may originate from 
LPGi.   
In the cerebellum, no negligible signal was detected in the granular layer and the 
Purkinje cell layer.  However, weak Nav1.5 immunoreactivity on some fibrous structures 
was observed in the cerebellar molecular layer, and intense Nav1.5 signals were   
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Fig. 4.3.  Co-localization of Nav1.5 and neurofilaments.  Confocal microscopic images 
of caudate putamen immunostained with both the anti-Nav1.5 antibody and the 
monoclonal anti-neurofilament 200 antibody. (a) immuno£uorescent image for Nav1.5 
protein, green; (b) immunofluorescent image for neurofilaments, red; (c) overlay of 
image A and image B. Bar = 200 µ m. 
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in the white matter of the cerebellum (Fig. 4.2H).  Nav1.5 immunoreactivity was found 
mostly in process-like structures, presumably neuronal processes.  Neuronal cell bodies 
and glial cells did not label with the Nav1.5 antibody.   
In conclusion, Nav1.5 protein is widely distributed throughout the central nervous 
system, and it is clustered much more densely in the neuronal processes than in the 
neuronal cell bodies.  
Confocal microscopic analysis to define the subcellular localization of Nav1.5 protein  
In the central nervous system, the neuronal processes showed strong Nav1.5-
immunoreactivity, whereas the cell bodies showed no or very weak signal (Fig.4.2C).  To 
further characterize the localization of Nav1.5 at the subcellular level, we performed 
double-immunostaining with mouse brain sections using both the rabbit anti-Nav1.5 
antibody described above and the anti-neurofilament antibody.  Fig. 3 shows confocal 
microscopic images of the caudate putamen of the basal ganglion.  Nav1.5 is clearly 
expressed in the nerve tracts identified by the anti-neurofilament antibody (Fig. 4.3A-C).  
A highly magnified image of the nerve fibers in this area showed that Nav1.5 
immunoreactivity (green) did not overlap with the neurofilament signals (red) (Fig. 4.3D-
F).  The Nav1.5 signals appeared outside the neurofilament compartment, consistent with 
the localization of Nav1.5 protein on the neuronal plasma membrane (Fig. 4.3F).  These 
data suggest that Nav1.5 protein is localized to the plasma membrane of the nerve 
processes and is not present in the interior.   
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4.5.  DISCUSSION 
In this report, we describe the immunohistochemical characterization of the 
regional and cellular distribution of the cardiac voltage-dependent sodium channel α-
subunit (Nav1.5) protein in the mouse brain.  We found that the cell bodies of neurons did 
not contain Nav1.5.  Instead, we observed the striking and distinct subcellular localization 
of the Nav1.5 channels on the plasma membrane of neuronal processes (Fig. 4.3) that are 
specialized for conducting electrical signals.  This distribution is consistent with the 
functional role of sodium channels which are responsible for generation and propagation 
of the action potentials in the neurons and for conducting electrical signals throughout the 
nervous system.   
The distribution of the cardiac sodium channel Nav1.5 in the brain has not been 
previously characterized at the protein level.  Our study represents the first detailed 
characterization of Nav1.5 protein distribution in the mouse brain.  Consistent with the 
distribution of Nav1.5 transcripts in rat and human brain (Donahue et al. 2000; Hartmann 
et al. 1999), the mouse Nav1.5 protein was present in the olfactory system, thalamus, and 
hypothalamus.  However, our study revealed localization of Nav1.5 protein in several 
brain regions that were not described or analyzed in previous studies.  These regions 
include the cerebral cortex, basal ganglia, and the white matter of the cerebellum.  
Another difference between our study and the previous reports is related to the limbic 
system.  Hartmann et al. and Donahue et al. showed strong expression of Nav1.5 mRNA 
in the piriform cortex, septal nuclei, the diagonal band of Broca, amygdala, and habenular 
nuclei, whereas our study did not detect Nav1.5 protein in these structures.  Instead, we 
found weak or moderate presence of Nav1.5 protein in the nerve fibrous structures in 
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these regions.  A possible explanation for the difference between our study and the 
previous studies may be that Nav1.5 mRNA is localized to the neuronal cell bodies, 
whereas the Nav1.5 protein molecules are synthesized in these locations, and are 
transported to and accumulate in the neuronal processes.   
          The implications of our study are two-fold:  (1) Increasing evidence suggests that 
the distinctive roles played by different brain Na channels are often dictated by their 
unique localization in excitable tissues.  Our finding that Nav1.5 protein is localized in the 
neuronal processes in certain distinct regions of the brain, as well as the fact that 
activation and inactivation of the Nav1.5 channels are voltage-dependent, may suggest 
that Nav1.5 could aid in efficient nerve impulse generation and propagation in these 
specific brain regions.  Together with SCN12A, Nav1.5 channels generate the TTX-
resistant sodium currents in the brain, which may play a role in sustained firing of 
neurons or as pace-makers;  (2)  We and others have established that mutations in Nav1.5 
cause cardiac arrhythmias and sudden cardiac death associated with long QT syndrome 
(LQTS), idiopathic ventricular fibrillation/Brugada syndrome, and cardiac conduction 
disease (Chen et al. 1998; Wan et al. 2001; Wang et al. 1995b).   
It has been recognized that the nervous system also plays a role in the genesis of 
cardiac arrhythmias.  Fright, anger, depression, intense emotion, rigorous exercises, 
swimming, alarm clocks, ringing telephones, and other activities related to the nervous 
system can all trigger life-threatening arrhythmias.  For LQTS, major genes have been 
cloned or identified as the cardiac sodium channel gene Nav1.5 (LQT3) and potassium 
channel subunit genes KCNQ1 (LQT1), and KCNH2 (LQT2) (reviewed in (Wang et al. 
2001).  Genotype-phenotype correlation studies (Schwartz et al. 2001) found that LQT2 
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and LQT3 patients with mutations in Nav1.5 and KCNH2 (both of them are expressed in 
the brain (Curran et al. 1995; Donahue et al. 2000; Emmi et al. 2000; Hartmann et al. 
1999) frequently develop cardiac arrhythmias during sleep or at rest, whereas LQT1 
patients with mutations in KCNQ1 (not expressed in the brain) (Wang et al. 1996) 
experienced cardiac events during exercise.  For idiopathic ventricular fibrillation with 
ECG characteristics of right bundle branch block and ST segment elevation (also known 
as Brugada syndrome), we established that Nav1.5 mutations that are functionally 
different from LQT mutations are the underlying causes of this disease (Chen et al. 1998).  
Interestingly, Brugada patients also develop life-threatening arrhythmias predominantly 
during sleep (Matsuo et al. 1999).  Although it is speculative and remains to be 
investigated, it is possible that mutant Nav1.5 proteins expressed in certain brain regions 
of LQT3 patients may play a role in generating the trigger to provoke arrhythmias during 
sleep or at rest.  Of particular interest is the expression of Nav1.5 in the brainstem which 
is known to be involved in regulating cardiac activities through autonomic motor neurons.     
 In conclusion, our results indicate that Nav1.5 protein is localized to the plasma 
membrane of the neuronal processes within distinct regions of the brain.  This study 
provides new insight into a possible physiological role of Nav1.5 in brain function.    
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CHAPTER V 
 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
      My thesis focuses on functional regulation of the cardiac sodium channel Nav1.5. 
First, I identified a novel regulatory protein, MOG1, as a key component of the cardiac 
sodium channel Nav1.5 protein complex.  I demonstrated that MOG1 exerted significant 
effects on the function of the cardiac sodium channel (see Chapter II).  The results 
provide insights into the structure and function of the Nav1.5 protein complex in the 
physiology of the cardiovascular system and reveal a novel functional role for MOG1. 
Regulation of Nav1.5 in the pathological state was studied in a mouse model for long QT 
syndrome, a lethal arrhythmia that causes sudden death, using genomic approaches.  I 
found that the LQT3 mutation N1325S in Nav1.5 was able to re-program the expression 
of many genes.  Of particular interest was the highly elevated expression of STAT1, 
which may be related to cardiomyocyte apoptosis in transgenic N1325S hearts (see 
Chapter III).  To explore possible novel functional roles in the brain, the expression 
profile of Nav1.5 protein was analyzed in the mouse brain.  I showed that the Nav1.5 
protein was localized to the plasma membrane of the neuronal processes within distinct 
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regions of the brain (see Chapter IV).  The results provide new insights into a possible 
physiological role of Nav1.5 in the brain.  Overall, my studies contribute to the field of 
the functional characterization of Nav1.5, and my results have also expanded current 
research of Nav1.5 to new directions that warrant future attention as described below.   
 
5.1. MOG1 acts as an important regulator for the function of Nav1.5 
      MOG1 interacts with cardiac sodium channel Nav1.5, and the presence/absence of 
MOG1 affects the sodium currents in both a heterologous transfection HEK293/Nav1.5 
cell line and native neonatal cadiomyocytes.  MOG1 was also shown to colocalize with 
Nav1.5 at the intercalated discs of cardiomycytes.  The results suggest that MOG1 may be 
critical for modulating the function of cardiac sodium channel.  There are several other 
proteins that have been identified and reported in the Nav1.5 interacting protein complex 
(Abriel et al. 2005, Allouis et al. 2006).  These proteins include structural proteins 
(ankyrin G, syntrophin/dystrophin), signaling proteins (FHF1B, calmodulin) and 
enzymes (Nedd4, Fyn, PKA, PKC, SGKs, PTPH1).  However, none of these proteins 
have been shown to play a role in Nav1.5 function in a physiological context.  The 
functional study for these proteins were all performed in heterologous cell expression 
systems, but not in native cardiac cells, and the effects on Nav1.5 were only evaluated by 
overexpressing the potential interacting protein(s).  We have analyzed the effects of 
MOG1 on Nav1.5 in cardiomyocytes and examined the sodium current by knocking down 
MOG1 expression in the mouse.  It will be interesting to use siRNA technology to knock 
down expression of the other Nav1.5-interacting proteins and compare their effects on 
sodium currents to the effects we observed for MOG1. 
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5.1.1.  MOG1 may be involved in cell-cell communication  
This thesis revealed the physiological function(s) of MOG1 in mammalian cells.  
A previous study with Northern blot analysis demonstrated that the heart was the tissue 
with the highest expression level of MOG1, suggesting that MOG1 plays an important 
role in cardiac function (Marfitia et al.2001).  The results from the present study further 
define the role of MOG1 in the heart.  We provide evidence that MOG1 the expression of 
MOG1 was highly expressed in the intercalated discs of both atrial and ventricular cells 
(Fig 2.8C), and colocalized with Nav1.5 at the intercalated discs of cardiomyocytes (Fig 
2.8E).  Moreover, the expression pattern of MOG1 was similar to the pattern shown by 
connexin 43 (Fig 2.8C-D), the principal connexin of the working myocardium that 
constructs the gap junction at intercalated discs of cardiac tissue.  In addition, our results 
are consistent with those of Malhotra research group whose work demonstrated that 
Nav1.5 colocalizes with connexin-43 (Malhotra et al. 2004).  Taken together, MOG1 and 
Nav1.5 colocalize with connexin 43 at the intercalated disc of cardiomyocyte.  The 
expression of Nav1.5 at the intercalated disc implies that the action potential may jump in 
saltatory fashion from one end of the cell to the other end via Nav1.5 channels (Sebastian 
et al. 2001).  It is speculated that co-localization of MOG1 and Nav1.5 at the intercalated 
disc may play an important role in establishing and regulating electrical connections 
between cardiomyocytes.  Further analysis will be necessary to test this hypothesis.  On 
the other hand, our results shown MOG1 facilitates Nav1.5 expression on cell surface, 
which suggests that MOG1 increases the conduction velocity of electrical impulse in 
cardiac tissue.   
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5.1.2.  The possible molecular mechanisms for regulating the function of Nav1.5 by 
MOG1 
As demonstrated in Chapter IV, our results revealed an increase in Nav1.5 
expression level in the plasma membrane and an increase in sodium currents when over-
expressed with MOG1 (Fig 2.9).  The detailed molecular mechanism by which MOG1 
regulates the functional expression of Nav1.5 on plasma membrane remains to be further 
defined.  I showed that increased cell surface expression of Nav1.5 by MOG1 may be a 
mechanism for increased sodium current densities by MOG1 and may potentially be 
achieved through increased transport of Nav1.5 to cell surface and/or reduced 
internalization/degradation of Nav1.5.   
The trafficking of membrane proteins like Nav1.5 is a highly regulated process. 
After being synthesized on ribosomes, the protein is incorporated into the endoplasmic 
reticulum (ER), then transported from ER to the Golgi apparatus, and subsequently 
trafficked to the cytoplasmic membrane.  A critical step in this process is the transition 
from the ER to Golgi compartment, which is reported to be related to the ER retention 
motifs and ER export signals (Zhou et al. 2002).  Little is known about regulation of 
sodium channel transport from cis face to trans face of the Golgi complex, and from the 
Golgi to the plasma membrane. There is a potential ER export signal (DXE) in the C-
terminus of Nav1.5 that may regulate the exit of fully folded and assembled Nav1.5 out of 
the ER (Herfst et al. 2004).  Recently, ER retention signal (RXR), which retains newly 
formed proteins in the ER, has been shown to play an important role in the trafficking of 
many membrane proteins to the cell surface including calcium channel alpha1 subunit, 
ATP-sensitive K+ channel, GABAB receptor and NMDA receptor (Bichet et al. 2000, 
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Zerangue et al. 1999, Margeta-Mitrovic M, Scott et al. 2001).  Lily Jan and colleagues 
first demonstrated the function of ER retention motif RXR in ATP-sensitive K+ channel 
trafficking to plasma membrane, and later Bichet et al. found that this retention motif also 
mediated trafficking of Ca2+ channel α1 subunit to cell surface and proposed that binding 
of β subunit is a mechanism for facilitating movement of channels to plasma membrane 
by masking the ER retention signal in the α1 subunit (Bichet et al. 2000, Zerangue et al. 
1999).    
Inspection of the sequence of Nav1.5 revealed a total of six ER retention motifs 
(RXR).  Three ER retention signals are located in loop I between DI and DII which are 
involved in mediating the trafficking of sodium channels by PKA (Zhou et al. 2002), one 
at the C-terminus (at 2010-2012) next to the PDZ domain which is the interacting site for 
syntrophin and PTPH1, and two at the cytoplasmic loop II between DII and DIII (at 986-
988 and 1193-1195) with unknown functions.  Whether the two ER retention motifs in 
Nav1.5 loop II play a similar role as those in KATP and calcium channels is an interesting 
question.  A working model is illustrated in Fig. 5.1.  It should be interesting to test 
whether these two ER retention motifs (RHR for 986-988 and RLR for 1193-1195) play 
any role in the regulation of Nav1.5 trafficking to cell surface by MOG1.  The two ER 
retention motifs can be mutated and their effects on trafficking of Nav1.5 to cell 
membrane can be analyzed by expressing wild type and mutant channels in mammalian 
cell lines and comparing their differences on the expression levels on cell membrane.  
The effects of MOG1 on ER retention can be tested by introducing a chimeric protein 
CD8-loop II-Myc, in which the entire cytoplasmic sequence of CD8 is replaced by the 
loop II-Myc sequence.  This chimeric protein is then expressed in mammalian cell lines 
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Fig. 5.1.  A model for the MOG1-mediated increase in cell surface expression of 
sodium channel Nav1.5.  We have demonstrated that MOG1 is involved in the 
trafficking of Nav1.5 to cell membrane.  In the absence of MOG1, Nav1.5 is trapped 
within the ER by binding onto an ER retention protein (ERRP) through the ER retention 
motif(s) in the loop II.  In the presence of MOG1, binding of MOG1 to Nav1.5 loop II 
releases the retention brake and facilitates the transport of Nav1.5 to the plasma 
membrane.  The amino acids sequence of Nav1.5 loop II is shown upper left corner with 
the two ER retention motifs highlighted.  This model was adapted from Bichet D et al. 
2000. Neuron 25:177–190. 
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in the presence or absence of MOG1.  The intracellular distribution of CD8-loop II-Myc 
can be visualized by immunostaining.  In the presence of MOG1, CD8-loop II-Myc is 
expected to be mainly localized on cell membrane.  These results will indicate that 
MOG1 is required for ER exit of Nav1.5.  To determine whether the increased cell 
surface expression of Nav1.5 was the result of overexpression of MOG1 (by the 
mechanism of enhanced ER exit of Nav1.5), we can compare the intracellular localization 
of Nav1.5 in the presence or absence of MOG1.  ER marker calnexin and Golgi marker 
GM130 can be used to visualize the position for ER and cis-Golgi separately, as 
described previously (Liu et al. 2007).  Nav1.5 signals are expected to be increased in 
Golgi and reduced in ER in the presence of MOG1 if MOG1 promotes trafficking of 
Nav1.5 from the ER to Golgi complex.  
 
5.1.3.  Future Directions 
Determination of the binding domains for the Nav1.5-MOG interaction  Eight 
mutations associated with Brugada syndrome, long-QT syndrome and sudden infant 
death have been identified in the cytoplasmic loop II of Nav1.5 (Appendix A).  The 
mutation E1053K in Nav1.5 causing Brugada syndrome was shown to interrupt the 
localization of Nav1.5 to cell surface mediated by ankyrin G (Mohler et al. 2004).  In this 
study we showed that MOG1 is another Nav1.5 cytoplasmic loop II interacting protein.  
However, the specific binding sites in MOG1 and loop II of Nav1.5 remain to be 
identified.  In the future, serial deletion analysis and site-directed mutagenesis in 
combination with protein binding assays can be employed to identify the binding site(s).  
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When a binding site is identified, it will reveal whether any disease-associated mutations 
are located within the site and affect the binding of MOG1 to Nav1.5.  
MOG1 may have effects on other sodium channels  The sequence of Nav1.5 loop 
II is highly homologous to two sodium channel isoforms, Nav1.8 and Nav1.9 which are 
predominantly expressed in dorsal root and trigeminal ganglia (DRG).  It is reasonable to 
speculate that MOG1 may associate with these two sodium channels and has similar 
biological effects on them as it does on Nav1.5.  Similar experiments for studying Nav1.5 
and MOG1 can be performed to test this hypothesis.  In addition, as shown in Chapter IV, 
Nav1.5 was demonstrated to be distributed widely through the central nervous system and 
mainly localized to the axons at the cellular level.  These results suggested that MOG1 
may associate with Nav1.5 in the brain and have effects on regulating neuronal 
excitability mediated by Nav1.5.  MOG1 can be co-expressed with expression constructs 
for Nav1.8 and Nav1.9 or other sodium channels in HEK-293 cells, and the effect of 
MOG1 can be determined by measuring the sodium currents.  These studies should be 
able to determine whether the effect of MOG1 is specific for Nav1.5.   
Identification of MOG1 mutations in arrhythmia patients  Nav1.5 mutations 
have been associated with Brugada syndrome and other types of lethal arrhythmias.  The 
fact that Nav1.5 mutations affect the cell surface expression (trafficking) suggests that 
MOG1 may also be central and/or a contributor to many disease processes in the heart.  
Genetic mutations in MOG1 may affect the expression and function of Nav1.5, leading to 
similar cardiac diseases.  Future mutational analysis of MOG1 in patients with various 
arrhythmic disorders can be performed to test this hypothesis.  On the other hand, 
identification of proteins like MOG1 that regulate expression and function of Nav1.5 may 
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serve as interesting targets for developing interventional options to manage lethal 
arrhythmias associated with Nav1.5 mutations or abnormalities.  Furthermore, the present 
findings provide new insights into the physiological role of MOG1 in vivo in mammalian 
cells, and future studies of MOG1 will likely offer more insights on its role and its 
relevance in myocardial function. 
 
5.2. The increased expression of STAT1 in SCN5A N1325S transgenic mouse may 
be involved in cardiomyocyte apoptosis 
Abnormal calcium handling has been demonstrated in SCN5A N1325S transgenic 
mice (Yong et al. 2007).  Calcium ion antagonist verapamil was shown to reduce the 
incidence of inhomogeneous AP in SCN5A N1325S transgenic mice (Yong et al. 2007).  
This finding suggests that SCN5A N1325S mutation causes the remodeling of 
intracellular calcium ion homeostasis in response to the [Na+]i overload.  It was reported 
that increased intracellular Ca2+ concentrations enhanced the phosphorylation of STAT1 
and thus increased transcription activation of STAT1-dependent genes (Xu et al. 2005, 
Nair et al. 2002).  Indeed, several STAT1 mediated genes were also expressed abundantly 
as a result of SCN5A N1325S mutation (see chapter III).  There is not yet direct 
experimental evidence for the relationship between the expression level of STAT1 and 
intracellular calcium influx.  In the future, TG-NS mice can be treated with calcium 
channel blockers (TG-WT as control), and [Ca2+]i and expression of STAT1 can be 
measured.  Decreased [Ca2+]i by calcium channel blockers may correlate with reduced 
expression of STAT1, which will support the hypothesis that increased STAT1 
expression in TG-NS mice may be related to abnormal calcium handling in these mice.  
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In our study, STAT1 has been shown to be highly expressed in SCN5A N1325S 
transgenic mice (Chapter III).  STAT1 has been shown as a preapoptotic factor.  
Apoptosis was observed in our SCN5A N1325S transgenic mice (Zhang et al. 2007).  
Therefore, STAT1 may mediate apoptosis in SCN5A N1325S transgenic mice.  To test 
this hypothesis, TG-NS mice can be breed to STAT1 knockout mice to determine 
whether the absence of STAT1 can prevent apoptosis induced by SCN5A mutation 
N1325S in TG-NS mice. 
 
5.3. Nav1.5 is a candidate gene for brain disease 
      Chapter IV showed that the Nav1.5 protein was widely expressed in the central 
nervous system, including the cerebral cortex, striatum, cerebellum, and brain stem.  
Nav1.5 was also detected on the plasma membrane of the neuronal processes within 
distinct regions of the brain.  The implication of this finding is that Nav1.5 may play a 
role in the physiology of the central nervous system.  Interestingly, administration of 
propranolol, which has a potential to block sodium channels, can correct the disorder of 
habituation in schizophrenic patients.  Recent work from Roberts et al. found that “an 
aboriginal genetic defect in voltage-gated Na+-channel SCN5A can give rise to 
susceptibility to schizophrenia” (Roberts et al. 2006).  It has been known that another 
type of sodium channel blocker, local anesthetics, can act as an anticonvulsant by 
producing a conduction block in nerves and prevent a variety of seizures.  On the other 
hand, anticonvulsants such as phenytoin have a therapeutic effect for cardiac arrhythmias 
by blocking sodium currents (Rogawski et al. 1990).  Abnormal neuronal activity 
associated with Nav1.5 mutations might affect both the coordination of brain function and 
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cardiac rhythm, which may trigger seizures, syncope, life-threatening arrhythmias, or 
sudden death in arrhythmic and epileptic patients.  Screening Nav1.5 mutations in 
schizophrenia and epilepsy patients may provide additional evidence to support this 
hypothesis.   
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Appendex A.     Summary of mutations associated with the Nav1.5 gene 
Mutation 1     Coding effect        Region2 Disease3 Reference 
G9V Missense N-terminal LQT3 Millat G et al, 2006 
R27H Missense N-terminal BS Priori S et al. 2002 
G35S Missense N-terminal BS Nissenbaum E et al. 2001 
Q55X Nonsense N-terminal BS Makita N et al. 2007 
V95I    Missense N-terminal BS Liang P et. Al. 2006.
R104Q Missense N-terminal BS Nissenbaum E et al. 2001 
 Splicing 
insertion 
N-terminal BS Sangwatanaroj S et al. 
2002 
K126E Missence DIS1 BS Vatta M et al. 2002 
E161K Missense DIS2 BS/SSS/ 
PCCD 
Smits J et al. 2002; Smits 
JP, 2005   
T187I, Missense DIS2-S3 BS/SSS Makiyama T 2006 
20-bp 
Deletion 
Frame-shift and 
truncation 
DIS2–S3 BS Vatta M et al. 2002 
L212P Missense 
(Cx40) 
DIS3-S4 AS Makita N,2005  
S216L Missense DIS4 SIDS Wang DW et al. 2007 
T220I,   Missense DIS4 DCM/SS
S 
Olson TM, 2005, Benson 
DW 2003 
R225Q Missense DIS4 LQT3 Millat G, 2006 
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A226V Missense DIS4 BS Priori Set al. 2002 
I230V Missense DIS4 BS Priori Set al. 2002 
R282H Missense DIS5–S6 BS Priori Set al. 2002 
G292S Missense DIS5 -S6 BS Niimura H et al.2004 
V294M Missense DIS5–S6 BS Priori S et al. 2002 
NA Nonsense DIS5–S6 BS Smits J et al. 2002 
R282H Missense   DIS5-S6 BS Poelzing S et al.2006 
K317N Missense DIS5-S6 BS Yi SD, et al.2003 
G319S Missence DIS5–S6 BS Priori S et al. 2002 
P336L   Missense DIS5-S6 BS Cordeiro et al. 2006 
G351V Missence DIS5–S6 BS Vatta M et al. 2002 
T353I Missense DI S5-S6 BS Pfahnl AE et al. 2007 
R367H Missense DIS5–S6 BS Vatta M et al. 2002 
R367C Missense DIS5–S6 BS Smits J et al. 2002 
R367H Missense D1S5-S6 BS/AS Takehara N, 2004 
M369K Missense DIS5–S6 BS Smits J et al. 2002 
R376H Missense DIS5-S6 BS/PCCD Rossenbacker T, 2004 
D356N Missense DIS5-S6 BS Makiyama T 2006 
393delF Deletion DIS6 BS Priori S et al. 2002 
N406S Missense DIS6  BS Itoh H et al.  2005 
E473X   Nonsense DI-DII BS Baroudi G, 2004 
K493 Deletion DI–DII BS Smits J et al. 2002 
G514C Missense DI–DII PCCD Tan H et al. 2001 
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R535X Nonsense DI–DII BS Smits J et al. 2002 
   BS/SIDS Wan X et al. 2001 
A572D Missense DI-DII LQT3  
A572D Missense DI-DII LQT3 Paulussen A, 2003 
delAL586-
587 
in-frame deletion DI-DII SIDS Wang DW et al. 2007 
G615E Missense DI–DII LQT3S Yang P et al. 2002 
L618F Missense DI–DII LQT3S Yang P et al. 2002 
L619F Missense DI-DII  LQT3 Wehrens XH, 2003 
G639R Missense DI-DII   LQT3 Millat G, 2006 
R680H Missense DI-DII SIDS Wang DW et al. 2007 
H681P Missense DI–DII BS Priori S et al. 2002 
A735V Missense DIIS1 BS Vatta M 
A735E Missense DIIS1 BS Priori S et al. 2002 
G752R Missense  BS Smits J et al. 2002 
 Splice mutation DIIS2 BS Priori S et al. 2002 
2550-2551 
insTG 
insertion DIIS3-S4 DCM Olson TM, 2005 
W822X Nonsense DIIS4  BS Keller DI, 2005 
S835L Missense DIIS4 –S5  BS  
F851L Missense DIIS5 BS Priori S et al. 2002 
F861fs951X Nonsense DIIS5 BS Schulze-Bahr E, 2003 
E867X Nonsense DIIS5-S6 BS Schulze-Bahr E, 2003 
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L867X Missense DIIS5-S6 BS Smits J et al. 2002 
S871fs+9X Frame-shift DIIS5–S6 BS Priori S et al. 2002 
F891I Missense DIIS5–S6 BS Priori S et al. 2002 
C896S Missense DIIS5–S6 BS Priori S et al. 2002 
S910L Missense DIIS5–S6 BS Priori S et al. 2002 
NA Frame-shift DII-DIII BS Hofman-Bang J, 2006 
S941N Missense DII–DIII LQT3/SI
DS 
Schwartz Pet al. 2000 
R965C Missense DII–DIII LQT3/BS   Sangwatanaroj et al. 
2002,  Priori S et al. 2002 
A997S Missence DII–DIII SIDS Ackerman M et al. 2001 
E1053K Missence DII–DIII BS Priori S et al. 2002 
D1114N Missense DII–DIII LQT3/BS   Sangwatanaroj S et al. 
2002, Splawski I  et al. 
2002 
W1191X Missense DII-DIII BS Shin DJ et al. 2007 
R1192Q Missense DII-DIII BS Vatta M et al. 2002 
E1225K Missense DIIIS1 BS Smits J et al. 2002 
E1225K Missense DIIIS1-S2 BS Schulze-Bahr E, 2003 
R1232W Missence DIIIS1–S2 IVF/BS Chen Q et al. 1998 
R1232W 
R1232W+ 
T1620M 
Missense 
Missense 
DIIIS1–S2 
DIIIS1–S2 
IVF/BS 
IVF/BS 
Chen Q et al. 1998, 
Baroudi G et al. 2002 
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K1236N Missense DIIIS1–S2 BS Priori S et al. 2002 
E1240Q Missense DIII–S2 BS Priori S et al. 2002 
F1250L Missense DIII–S2 LQT3  Yang P et al. 2002 
NA Frame-shift  BS Smits J et al. 2002 
G1262S Missense DIII-S2 BS Shin DJ, 2004 
D1275N Missense DIIIS3 DCM/AF Olson TM, 2005, 
Groenewegen WA, 2003 
D1275N Missense DIIIS3 PCCD/AF Laitinen-Forsblom PJ, 
2006 
F1293S Missense DIIIS3–S4 BS Priori S et al. 2002 
E1295K Missense DIIIS4 LQT3 Abriel H et al. 2001 
P1298L Missense DIIIS4 SSS Benson DW, 2003 
T1304M Missense DIIIS4 LQT3/SI
DS  
Wattanasirichaigoon Det 
al. 1999 
Wang DW, 2007 
IVS22DS+2 Splice mutation DIIIS4–S5 PCCD Schott J et al. 1999 
G1319V Missense DIIIS4-S5 BS Smits J et al. 2002 
N1325S Missense DIIIS4–S5 LQT3 Wang Q et al. 1995 
A1330P Missense DIIIS4–S5 LQT3/SI
DS 
Wedekind H et al. 2001 
A1330T Missense DIIIS4-S5  LQT3 Smits JP et al., 2005 
S1333Y Missense DIII/S4-S5 SIDS Millat G et al., 2006 
F1344S Missense DIIIS5 BS/VF Keller DI et al., 2006 
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S1382I Missense DIIIS5-S6 BS Smits J et al. 2002 
V1398X Nonsense DIIIS5–S6 BS   Chen et al. 1998, 
Sangwatanaroj S et al. 
2002 
V1405L Missense DIIIS5–S6 BS Smits J et al. 2002 
G1406R Missense DIIIS5–S6 BS/PCCD 
/SSS 
 Smits J et al. 2002, Kyndt 
F et al. 2001 
Benson DW et al. 2003 
W1421X Missense DIIIS5-S6 LQT3 Niu DM et al.2006 
R1432G Missence DIIIS5–S6 BS Deschenes I et al. 2000, 
Baroudi G et al. 2001 
G1467fs+13
X 
Frame-shift DIIIS6 BS Priori S et al. 2002 
 Splice mutation c.4810+3_4
810+6dupG
GGT 
BS/PCCD Rossenbacker T et al.2005 
delK1479 Missense DIII-DIV BS Schulze-Bahr E et al. 2003 
F1486L Missense DIII-DIV SIDS Wang DW et al. 2007 
delK1500 Deletion DIII–DIV LQT3/BS Priori S et al. 2002 
L1501V Missense DIII–DIV LQT3 Splawski I et al. 2000 
G1502S Missense DIII–DIV BS Smits J et al. 2002 
1503 Deletion  LQT3 Wang Q et al. 1995 
delKPQ Deletion DIII–DIV LQT3  Wang Q et al. 1995  
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1505-1507  
R1512W Missense DIII–DIV BS Rook M et al. 1999, Smits 
J et al. 2002 
delQKP 
1507-1509 
Deletion DIII-DIV  LQT3 Keller DI et al. 2003 
IVS2AS-24 Splice mutation DIVS BS Rook M et al. 1999 
IVS21+1 Splice mutation  BS Smits J et al. 2002 
IVS24DS+28 Splice mutation DIVS BS Rook M et al. 1999 
K1527R  Missense   DIVS1 BS Yokoi H et al. 2005 
A1569P Missense   DIVS2 BS  
K1578fs/52 Missense DIVS2 BS/SSS Makiyama T et al. 2006 
26AS-
5insTGGG? 
Splice mutation 
(In-frame 
deletion) 
DIVS2-S3 BS Hong K et al. 2005 
D1595N Missense DIVS3 PCCD Wang D et al. 2002 
S1609W Missense DIVS3 LQT3 Millat G, 2006 
D1595H Missense DIVS3 DCM Olson TM, 2005 
delF1616 Deletion DIVS3-S4 LQT3 Splawski I et al.2000 
delF1617 Deletion DIVS3-S4 LQT3/BS
/SSS 
Splawski I et al.2000/Liang 
P et. al. 2006, 
Benson DW et al. 2003 
T1620M Missense DIVS3–S4 IVF/BS Chen Q et al. 1998,   
R1623X Nonsense DIVS4 SSS Benson DW et al. 2003 
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R1623Q Missense DIVS4 LQT3  Splawski I et al. 2000 
R1623L Missense DIVS4 LQT3 Splawski I et al. 2000 
R1644H Missense DIVS4 LQT3 Splawski I et al. 2000 
R1623X Nonsense DIVS4 BS/SSS Makiyama T et al.  2006 
R1623X Nonsense DIV-S4 BS Todd SJ et al. 2005 
R1632H Missense DIVS4 SSS Benson DW et al. 2003 
T1645M Missense DIVS4 LQT3 Wattanasirichaigoon D 
etla. 1999 
A1649V Missense DIVS4-S5 BS Liang P et. al. 2006.
I1660V Missense DIVS5 BS Cordeiro JM et al. 2006 
S1710L Missense DIVS5–S6 IVF Shirai N et al. 2002 
delS1710 Deletion  PCCD Schott J et al. 1999 
D1714G Missense DIVS5-S6  BS Amin AS et al.2005 
delG5130 Frame-shift DIVS5–S6 PCCD Schott J et al. 1999 
delG5280 Frame-shift DIVS5–S6 BS Schott J et al. 1999 
G1740R Missense DIVS5-S6 BS Baroudi G et al. 2004 
G1740R Missense DIVS5–S6 BS Priori S et al. 2002 
G1743R Missense DIVS5-S6 BS Valdivia CR et al. 2004 
G1743E Missense DIVS5-S6 BS Smits J et al. 2002 
V1763M Missense DIVS6 LQT3 Chang CC et al. 2004 
M1766L Missense DIVS6 LQT3/AV
block 
Valdivia C et al. 2002 
I1768V Missense  LQT3 Rivolta I et al. 2002 
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N1774+12X? Nonsense C-terminal BS Baroudi G et al. 2004 
V1777M Missense C-term LQT3  Lupoglazoff J et al. 2001 
E1784K Missense DIVS6 LQT3/BS Deschenes I et al. 2000 
S1787N Missense DIVS6 LQT3 Splawski I et al. 2000 
D1790G Missense DIVS6 LQT3 An Ret al. 1998 
1795insD Insertion DIVS6 LQT3/IV
F 
Bezzina C et al. 1999 
Y1795C Missense C-terminal LQT3 Rivolta I et al. 2001 
Y1795H Missense C-terminal BS        Rivolta I et al. 2001 
insD1796 Insertion C-terminal LQT3/BS Bezzina C et al. 1999 
S1812X Nonsense C-terminal BS Schulze-Bahr E et al. 2003 
D1819N Missense C-terminal LQT3 Millat G, 2006 
L1825P Missense  LQT3 Makita N et al. 2002 
R1826H Missense C-terminal SIDS/LQ
T3 
Ackerman M et al. 2001 
D1840G Missense C-terminal LQT3 Benhorin J et al.1998 
L1921stop Nonsense  BS Cormier J et al. 2002 
A1924T Missense C-terminal BS/IVF  Smits J et al. 2002, Rook 
M et al. 1999 
V1951L Missense C-terminal BS/SIDS Priori S et al. 2002,Wang 
DW, 2007 
F2004L, Missense C-terminal SIDS Wang DW et al. 2007 
P2006A Missense C-terminal SIDS Wang DW et al. 2007 
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1Standard single letter code is used for amino acids. X stands for nonsense mutation. 
Examples for the mutations are as the following. G9V stands for a mutant in which 
glycine is replaced by a valine at position 9.  IVS22DS+2 stands for a mutant that insert 
in +2 donor splicing site of intron 22.  delAL586-587 stands for a mutant where Alanine 
586 and Leucine 587 are deleted. 2Abbreviations for diseases are listed in List of 
Abbreviations. 
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Appendix B.  Positive clones obtained from a yeast two hybrid screen.  Different 
DNA fragment of Nav1.5 as bait (upper panel) were used to screen a cardiac human 
cDNA library, Further protein identification using the cytoplasmic loop II of Nav1.5 as a 
bait was shown in the bottom panel.   
 
 
Baits1 Number of positive clones 
 
N-terminus 
 
0 
DI-II Linker (Loop I) 
 
0 
DII-III Linker (Loop II) 
 
223 
DIII-IV Linker (Loop III) 
 
29 
C-terminus 
 
Self activating 
 
1The above table showed the results for yeast positive clones using baits from 5 
cytoplasmic domain of Nav1.5: N-terminus, loops I, II, III and C-terminus.      
 
 
 
 
2The number of hits represents the number of positive yeast clones for the identified 
protein. 
Hits number2 Name of the protein  Gen bank number 
2 Cardiac Troponin I M64247
7 MOG1A AF265206 
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Appendix C. Additional genes showing differential expression in TG-NS hearts by 
microarray analysis1
  
(A)  Genes involved in immune response 
Accession # Symbo
l 
Gene    P value Fold of 
change 
NM_010395 H2-T10 Histocompatibility 2, T region locus 
10 
2.6 x 10-5 13.3 
BC027328 Brd4 Bone marrow stromal cell antigen 2 4.5 x 10-5 12.0 
M16120 Tcrb-
V13 
T-cell receptor insulin B-chain 
reactive beta chain VNDNJC 
1.5 x 10-4 9.3 
L03353 Cd3z CD3 theta T-cell receptor subunit  2.2 x 10-4 -7.2 
 
(B)  Genes encoding enzymes 
Accession # Symbo
l 
Gene   P value Fold of 
change 
NM_016966 Phgdh 3-Phosphoglycerate dehydrogenase 6.0 x 10-5 53.8 
NM_008638 Mthfd2 Methylenetetrahydrofolate 
dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate 
cyclohydrolase 
3.6 x 10-4 13.3 
BC027199 Lrrk1 Leucine-rich repeat kinase 1 5.610-4 -6.5 
NM_080446 Helb Helicase (DNA) B 7.1 x 10-4 9.1 
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 (C) Putative genes or genes with unknown functions  
Accession # Symbo
l 
Gene    P value Fold of 
change 
BC020489 231001
6F22Ri
k 
RIKEN cDNA 9130022K13 gene 2.4 x 10-4 231.3 
BB741897 Vig1-
pendin
g 
cDNA clone F520004L04 gene, 
similar to viral hemorrhagic 
septicemia virus(VHSV) induced 
gene 1   
7.6 x 10-4 25.6 
AF099975 Slfn4 Clone I.M.A.G.E. consortium 
638739 schlafen4 
6.6 x 10-4 17.2 
AV212753 Asns RIKEN cDNA clone 2410118F17 
gene, similar to Asparagine 
synthetase 
4.1 x 10-4 13.4 
NM_030150 D11Lg
p2e 
DNA segment, Chromosome 11, 
Lothar Hennighausen 2,expressed 
2.1 x 10-4 25.4 
BB132493  cDNA clone 9830001A05 gene 5.8 x 10-4 11.2 
BB329808 AW261
460 
cDNA clone B630019O10 7.4 x 10-4 10.1 
BQ033138 Oasl 2 cDNA clone UI-1-CF0-axe-c-08-0-
UI 3-, mRNA sequence, similar to 
2-5 oligoadenylate synthetase-like 2
9.6 x 10-4 9.8 
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BC023105 BC023
105 
Clone:MGC:28198 
IMAGE:3989161 
6.7 x 10-4 7.7 
BB020681 Srr cDNA clone UI-1-CF0-axe-c-08-0-
UI 3-, mRNA sequence, similar to 
serine racemase 
4.4 x 10-4 5.3 
BB251523 Pycs cDNA clone A730046N23, similar 
to pyrroline-5-carboxylate 
synthetase short isoform 
2.1x 10-4 5.2 
1Genes involved in interferon-signaling pathways, apoptosis and inflammation are listed 
in Table 3.2. 
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